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"Hey! This is an excellent microbe. It is big for a microbe, easily visible, easy to breed in 
mice. It kills them proper and always. Where could I find a better microbe than this 
trypanosome, to help me find the magic bullet which is needed for the therapy? Alas! I wish I 
could find a dye that would heal one mouse, one tiny little mouse." 
Paul Ehrlich, early 1900 
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Summary 
 Human African trypanosomiasis (HAT) is a neglected disease caused by the 
protozoan Trypanosoma brucei, which is transmitted during blood-feeding tsetse fly bites. 
The disease is endemic covering 36 sub-Saharan African countries and mainly impacts poor 
people living in remote areas, for which satisfactory treatment does not exist. As such, this 
protozoal disease would never be viewed as viable target market for the pharmaceutical 
industry. Therefore, it is referred to as a neglected disease. 
 Man rarely become infected with the more virulent T. b. rhodesiense form, found in 
Eastern and Southern Africa, and more often with the chronic T. b. gambiense form, which 
occurs in West and Central Africa. Once the trypanosomes cross the blood brain barrier 
(BBB) the patients fall into a comatose state accompanied by neurological breakdowns and 
apathy resulting in death when left untreated. Chemotherapy remains the principal treatment 
for HAT and is based on four drugs: suramin, pentamidine, melarsoprol, eflornithine, and a 
recent approved eflornithine-nifurtimox combination. Reported severe side effects (e.g. 
melarsoprol), treatment failures of up to 25%, administration difficulties, and expensive 
medication urgently demand for safe, orally administered drugs, that are effective against 
both stages of HAT. 
 Natural sources like plants and fungi provide a rich biological diversity with unique 
pharmacophores created by evolution. According to the WHO, 65% of the world’s population 
still relies on traditional medicines as a primary source of healthcare. 
 This thesis describes the search of new natural products (NPs) from nature. Over the 
last seven years we collected 724 plants and 64 fungi. The material was subsequently 
extracted and tested in vitro against T. b. rhodesiense, Plasmodium falciparum (the 
causative agent of malaria), Leishmania donovani (leishmaniasis), and T. cruzi (Chagas 
disease) to find potential hits. From the total 2151 extracts, 17.9% showed activity of more 
than 50% at 4.81 μg/mL test concentration against at least one parasite, and 3.4% showed 
potency of more than 50% at 0.81 μg/mL test concentration, respectively. Overall the plant 
extracts had six times higher “hit-rates” (15.3%) than the fungi extracts (2.6%), both resulting 
in high potencies against T. b. rhodesiense and P. falciparum. Yet, with up to 5 millions fungi, 
which outnumber higher plants by 16:1, the kingdom remains a relatively poorly studied 
source of NPs. Three fungal extracts had determined IC50s below 10 ng/mL, making them up 
to three orders of magnitude lower than the most potent plant extracts, which indicate the 
antiprotozoal potential of fungi. These findings were underlined by the truffle Elaphomyces 
granulates in vivo activity when tested intraperitoneally (i.p.) at 50 mg/kg/d. T. b. rhodesiense 
infected mice remained parasite free for 14 days compared to the controls, which were 
euthanized after 7 days postinfection. 
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The liquid extract library contains 177 plant extracts produced from traditionally used 
antimalarial Iranian plants and from plants, which were reported in herbal books as 
antimalarial remedies in European Renaissance herbals. When activities of antimalarial 
traditionally used remedies were compared to randomly selected plants, a five times higher 
“hit-rate” was found for ethno-medically used plants (19.7%) than for randomly selected 
plants (4.5%). 
 One of the antitrypanosomal hits was a dichloromethane (DCM) extract of the 
cornflower Centaurea salmantica with a growth inhibition of 61% tested at 4.81 μg/mL 
against T. b. rhodesiense. HPLC-based activity profiling led to the identification of the 
sesquiterpene lactone (STL) cynaropicrin (CYN), which was the first plant NP to show in vivo 
efficacy in T. b. rhodesiense infected mice, treated i.p. at 10 mg/kg/b.i.d. for four consecutive 
days. Despite of more than 10’000 known STLs is a better understanding of the structural 
features, which contribute to activity, expedient. The established structure-activity 
relationship (SAR) study included 18 natural STLs and demonstrated that antitrypanosomal 
and cytotoxic effect depended on their α,β-unsaturated enone moieties. Many bioactivities of 
STLs have been attributed to a nucleophilic Michael-addition of these functional motifs to 
biological thiols. Considering that trypanosomes depend on their unique trypanothione-based 
redox system to deal with oxidative stress and to maintain a reducing intracellular milieu and 
that CYN contains reactive exocyclic α,β-unsaturated methylenes, we anticipated that the 
mechanism of action depended on a direct interference with glutathione (GSH) and 
trypanothione (T(SH)2) in the cells. After 5 min. of CYN’s exposure to trypanosomes, the 
intracellular thiol pool was completely depleted and a GS-CYN-monoadduct as well as a T(S-
CYN)2-bisadduct were formed. This led to apoptosis of the trypanosomes over 40 min. linked 
to phenotype transformations from the typical slender to a stumpy-like form. Additionally, 
ornithine quantification studies by tandem mass spectroscopy (MS/MS) showed that 
ornithine decarboxylase (ODC) is a potential secondary target for CYN.  
 To improve CYN’s pharmacokinetic (PK) profile the α,β-unsaturated exocyclic 
double bond at the lactone was masked to create an amine prodrug with increased aqueous 
solubility and reduced unspecific binding to biological thiols. Through subsequent 
bioactivation the prodrug would be converted back to CYN and it would display a higher 
concentration on the target side. The lead optimization did not reward any better 
antitrypanosomal in vivo efficacy after oral application, but the prodrug had an improved in 
vivo cytotoxic profile. Further PK studies with other orally applied STL amino derivatives are 
needed to demonstrate if the use of amino STLs as prodrugs is a reasonable approach to 
improve STLs suitability as antitrypanosomal drug. 
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Zusammenfassung 
  Die Afrikanische Schlafkrankheit ist eine vernachlässigte Krankheit, die durch 
die Protozoen Trypanosoma brucei verursacht und während eines Blutmahls der 
Tsetsefliege übertragen wird. Die Krankheit ist in 36 subsaharischen Ländern Afrikas 
endemisch und betrifft hauptsächlich arme Einwohner in abgelegenen Orten, für welche 
zufriedenstellende Behandlung nicht zur Verfügung steht. Weil sie die teuren Therapien sich 
nicht leisten können, wird diese Protozoenerkrankung als nicht-profitabler Markt für die 
pharmazeutische Industrie angesehen. 
  Die Menschen werden selten mit der ansteckenderen T. b. rhodesiense Form, die in 
Ost- und Südafrika aufgefunden wird, infiziert, als mit der chronischeren T. b. gambiense 
Form, welche in West- und Zentralafrika auftritt. Wenn die Trypanosomen einst die 
Bluthirnschranke überquert haben, fallen die Patienten in einen komatösen Zustand, der von 
neurologischen Zusammenbrüchen und Teilnahmslosigkeit begleitet wird. Wenn die 
Patienten keine Behandlung bekommen, führt dies unweigerlich zum Tode. Die 
Chemotherapie verbleibt die einzige Kontrolle der Afrikanischen Schlafkrankheit und basiert 
auf vier Medikamente: Suramin, Pentamidin, Melarsoprol, Eflornithin, und eine kürzlich 
freigegebene Eflornithin-Nifurtimox Kombination. Gemeldete schwerwiegende 
Nebenwirkungen (z.B. von Melarsorpol), erfolglose Behandlungen in bis zu 25% der Fälle, 
schwierige Verabreichung, und die teure Medikation verlangen dringend sicherere, oral 
verfügbare Medikamente, die effektiv gegen beide Stadien der Afrikanischen Schlafkrankheit 
sind.  
 Natürliche Quellen wie Pflanzen und Pilze liefern eine reiche biologische Diversität 
mit einzigartigen Pharmakophoren, die von der Evolution kreiert wurden. Gemäss WHO 
haben 65% der Weltpopulation Zugang zu traditionell-verwendeter Medizin. 
 Diese Arbeit beschreibt die Suche nach neuen Naturstoffen. Während den letzten 
sieben Jahren haben wir 724 Pflanzen und 64 Pilze gesammelt, das Material extrahiert und 
in vitro gegen T. b. rhodesiense, Plasmodium falciparum (Erreger der Malaria), Leishmania 
donovani (Leishmaniose), und T. cruzi (Chagas Krankheit) getestet, um potentielle Hits zu 
finden. Von insgesamt 2151 Extrakten zeigten 17.9% eine Aktivität von mehr als 50% bei der 
Testkonzentration von 4.81 μg/mL gegen mindestens einen Parasiten, respektive 3.4% 
zeigten mehr als 50% Hemmung bei 0.81 μg/mL Testkonzentration auf. Insgesamt hatten die 
Pflanzenextrakte einen sechsmal höheren Anteil aktiver Hits (15.3%) als die Pilzextrakte 
(2.6%). Mit bis zu fünf Millionen übertreffen Pilze die Anzahl an Pflanzen 16:1, jedoch 
verbleiben sie eine verhältnismässig schlecht erforschte Naturstoffquelle. Drei Pilzextrakte 
hatten IC50s unter 10 ng/mL, welche im Vergleich zu den getesteten Pflanzenextrakten bis zu
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drei Ordnungsgrössen kleiner waren. Dieses Resultat wird vom Trüffel Elaphomyces 
granulates in vivo Aktivität, welcher intraperitoneal mit einer Dosis von 50 mg/kg/Tag getestet 
wurde, unterlegt. Die mit T. b. rhodesiense infizierten Mäuse waren für 14 Tage parasitenfrei 
im Gegensatz zur Kontrolle, welche nach 7 Tagen Postinfektion getötet wurden.  
 Die getestete Flüssigextrakt-Bibliothek beinhaltete 177 Pflanzenextrakte, die von 
traditionell genutzten iranischen Pflanzen und von Pflanzen, welche in Kräuterbüchern aus 
der europäischen Renaissanceepoche gegen Malaria dokumentiert sind, hergestellt wurden. 
Wenn die Aktivitäten der traditionell verwendeten Pflanzen mit den zufällig ausgewählten 
Pflanzen verglichen wurden, war die Hitrate für die traditionell genutzten Pflanzen (19.7%) 
fünf Mal höher als die der zufällig ausgewählten Pflanzen (4.5%) (definiert als > 50 % 
Hemmung bei 4.8 µg/mL).  
Einer der aktiven Hits gegen T. b. rhodesiense war der Dichlormethanextrakt der Kornblume 
Centaurea salmantica mit einer Wachstumsinhibition von 61% bei 4.81 μg/mL 
Testkonzentration. HPLC-basiertes Aktivitätsprofiling führte zur Identifizierung des 
Sesquiterpenlacton Cynaropikrin, welche der erste Naturstoff ist, der bei T. b. rhodesiense 
infizierten Mäuse in vivo Wirksamkeit aufzeigte, welche mit 10 mg/kg/b.i.d. intraperitoneal für 
4 Tage behandelt wurden. Trotz 10‘000 bekannten Sesquiterpenlactonen ist ein besseres 
Verständnis für Strukturmerkmale, die zur einer Steigerung der Aktivität beitragen, sinnvoll. 
Die darauffolgende Struktur-Aktivitäts-Beziehungs-Studie beinhaltete 18 
Sesquiterpenlaktone und zeigte auf, dass die trypanosomale Wirksamkeit und die 
Zytotoxizität auf dem Vorhandensein von α,β-ungesättigten Enon-Gruppen zurückzuführen 
ist. Viele biologische Wirksamkeiten der Sesquiterpenlactone wurden der nukleophilen 
Michael-Addition von α-Methylen-γ-lacton Gruppen mit Thiolen zugeschrieben. Unter der 
Betrachtung, dass die Trypanosomen von ihrem einzigartigen auf trypanothion-basierenden 
Redoxsystem abhängig sind, um den oxidativen Stress einzudämmen und das intrazelluläre 
reduzierende Milieu aufrechtzuerhalten, und dass Cynaropikrin reaktive α,β-ungesättigte 
Methylengruppen besitzt, haben wir antizipiert, dass der zelluläre Wirkmechanismus des 
Cynaropikrins von dessen direkter Interferenz mit Glutathion und Trypanothion 
zusammenhängt. Nach 5-minütiger Aussetzung zu den Trypanosomen war der intrazelluläre 
Thiolpool komplett aufgebraucht und ein GS-CYN-Monoaddukt sowie ein T(S-CYN)2-
Bisaddukt wurden geformt, welche zu einer Apoptosis der Trypanosomen während 40 min. 
führte. Während diesem Zeitfenster veränderte sich der Phänotyp von ihrer typischen 
„slender“ zu einer „stumpy“-ähnlichen Form. Zusätzlich, zeigten 
Ornithinquantifizierungsstudien mit Tandem-Massenspektrometrie, dass die 
Ornithindecarboxylase ein zusätzliches Target für Cynaropikrin ist. 
 X 
 
 Um das pharmakokinetische Profil von Cynaropikrin zu verbessern, wurde die α,β- 
ungesättigte exozyklische Doppelbindung am Lacton maskiert, um ein Amin-Prodrug mit 
gesteigerter Wasserlöslichkeit und reduzierter unspezifischen Bindungen an Thiolen 
herzustellen. Durch subsequente Bioaktivierung des Prodrugs würde das Molekül zurück zu 
Cynaropikrin konventiert werden was zu einer erhöhten Konzentration am Zielort führen 
würde. Die Optimierung hatte nach einer oralen Applikation des Prodrugs nicht zu einer 
gesteigerten antitrypanosomalen in vivo Aktivität geführt, jedoch zeigte der Prodrug ein 
verbessertes in vivo Zytotoxizitäts-Profil auf. Weitere pharmakokinetische Studien mit 
zusätzlichen oralen verabreichten Sesquiterpenlacton-Aminoderivaten sind nötig, um zu 
demonstrieren, ob die Nützlichkeit der Amino-Prodrugs als trypanosomale Arzneistoffe 
angemessen ist. 
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CHAPTER 1 
General introduction 
 On the WHO list of the most frequent worldwide causes of death by illness one found 
seventeen infectious diseases [1]. Among them are protozoan infections like malaria, 
sleeping sickness and schistosomiasis, which affect hundreds of millions worldwide resulting 
in significant mortality and social and economic consequences. The diseases mainly impact 
poor people living in remote areas, urban slums, and conflict zones with limited access to 
adequate health care services. For these diseases satisfactory treatment does not exist in 
terms of limitations in efficacy, severe side effects, high production costs, and complex 
administration patterns. As such, protozoal diseases would never be viewed as viable target 
markets for the pharmaceutical industry. Therefore they are referred to as neglected 
diseases [2]. In fact it nowadays costs the pharmaceutical industry 1 billion dollars and more 
than 10 years to develop a new drug [3]. Not surprisingly, the pharmaceutical industry would 
rather focus on Western life style diseases like diabetes (2010, nearly 26 million people have 
diabetes in the United States, 132 billion costs each year [4]), heart disease (63% of all 
deaths in the world [5]), and cancer (globally accounted for 7.6 million deaths 2008 [6]) to 
make a financial profit to cover the tremendous development costs than on the less lucrative 
tropical protozoal diseases. Therefore, development of new antiprotozoal drugs is a 
challenge. The good news is that in the last few years several non-profit drug research and 
development organizations like the Drugs for Neglected Disease Initiative (DNDi) [7], 
Medicines for Malaria Venture (MMV) [8], the World Health Organization (WHO), as well as 
academic centers significantly changed the way antiprotozoal drug development is done. 
DNDi and MMV function as project managers and bring together the components necessary 
to restock the drug pipeline. Additionally, enhanced funding possibilities coming largely from 
the Bill & Melinda Gates Foundation who spent 1.9 Bio. dollars for global health in 2011[9], 
Wellcome Trust [10] and the Sandlers Family Supporting Foundation [11], indicates a silver 
lining on the horizon. Funding of research is a crucial issue in antiprotozoal drug 
development, because the drugs will have to be cheap to produce. 
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1.1.  Human African trypanosomiasis (sleeping sickness) 
1.1.1. Vector and parasite 
 One of the most neglected diseases is Human 
African trypanosomiasis (HAT) with 30’000 estimated 
cases per year [12]. The disease is restricted to 36 sub-
Saharan countries based on the distribution of its vector, 
the tsetse fly Glossina sp. Glossina palpalis occurs in 
West and Central Africa in habitats with tropical forests 
and transmits Trypanosoma 
brucei gambiense whereas 
Glossina morsitans (Figure 1), Glossina pallidipes, and Glossina 
swynnertoni, breed in grassland, savannah, and woodland of 
Eastern and Southern Africa and transmit the parasite Trypanosoma 
brucei rhodesiense [13] (Figure 2). People become infected only 
sporadically with the rare, but more virulent T. b. rhodesiense form, 
which reflects 5% of the reported cases [14]. Patients infected with 
the chronic form of HAT caused by T. b. gambiense are still able to work over long periods 
despite the infection. Animals can host the pathogen, especially T. b. rhodesiense. Thus 
domestic and wild animals such as cattle, sheep, and goats are important parasite reservoirs 
[15]. 
1.1.2.  Clinical manifestation features 
  Unicellular trypanosomes are transmitted by the bite from a blood-feeding tsetse fly. 
At the puncture site a chancre appears. This is a sign of the localized proliferation of 
pathogens within the tissue accompanied by an inflammatory response and odema. The 
trypanosomes then spread into the lymphatic system and later enter the blood flow, which 
causes irregularly relapsing fevers with swollen lymph glands. This first phase of the infection 
is called the hemolymphatic stage. This phase endures dependent on the species for days 
(T. b. rhodesiense) or weeks (T. b. gambiense). The following second stage is caused by the 
invasion of the parasites through the blood brain barrier (BBB) into the cerebrospinal fluid, 
which is characterized by severe headache, apathy, and a progressive breakdown of 
neurological functions. In the comatose state the patients drift into what gave sleeping 
sickness its name [14]. 
Figure 1. T. b. 
rhodesiesene STIB 900 
strain; Giemsa stain  
(2012, Zimmermann) 
Figure 1. Glossina morsitans (Wilson 
[16]) 
2
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1.1.3. Treatment 
Since the clinical features of the first 
stage of the disease are not 
sufficiently specific and resemble a 
general malaise syndrome, 
exhaustive laboratory examinations 
of the population are required. In 
Africa resources are often scarce, 
particularly in remote areas where the disease is found. As a result, many individuals may 
die before they can ever be diagnosed and treated. The earlier the disease is identified, the 
better is the prospect of cure [14]. If patients are left untreated the disease is 100% fatal. 
Vaccination is not an option because of antigenic variation where the parasites repeatedly 
change their surface coat und thus evade the immune system [17]. Therefore chemotherapy 
remains the principal control of HAT, despite setbacks due to resistance [18,19]. The current 
treatment of sleeping sickness is based on whether the trypanosomes have infiltrated the 
central nervous system (CNS) (stage 2) or not (stage 1). This makes the chemotherapy of 
sleeping sickness difficult because the most effective drugs do not cross BBB and are thus 
not able to kill the parasites in the CNS. Additionally, treatment is limited and complex due to 
the only few available drugs, which have poor safety and unfavourable pharmacokinetic (PK) 
profiles. At present the licensed anti-HAT drugs are manufactured by the pharmaceutical 
companies Sanofi-Aventis (pentamidine, melarsoprol, and eflornithine) and Bayer Health 
Care (suramin). The drugs are donated for free to the WHO, which distributes them to the 
patients in Africa [12]. The following two drugs for the first stage infection are recommended 
by WHO (Figure 4). 
Pentamidine (Pentacarinat®): 
 After it was shown 1937 that trypanosomes consume an enormous amount of sugar 
in order to reproduce [20], Yorke and Lourie tested synthalin, a known oral antidiabetic drug, 
in vivo [21]. Although synthalins mode of action had nothing to do with the glucose level, the 
Figure 3. In man the bloodstream forms 
show polymorphism with (A) dividing 
slender forms, (B) intermediate forms, 
(C) stumpy forms. In the tsetse fly 
vector, bloodstream forms transform 
into (D) dividing midgut forms, then to 
(E) the migrating epimastigote forms, 
which develop in the salivary glands to 
(F) the infective metacyclic forms, 
which are injected during the next 
blood meal into the mammalian host 
[2]. 
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drug showed a trypanocidal effect. Further modification was done leading to a series of 
aromatic diamidines. Among them is pentamidine, which is chemically related to the 
antidiabetic drug phenformin [22]. At present pentamidine is still the drug of choice for 
treating the first stage T. b. gambiense infection. 
Suramin (Germanil®):  
 Back in the early 1900s, Paul Ehrlich and his assistant Shiga tested more than 100 
synthetic dyes for their in vivo utility to treat horses with Mal de Caderas, a disease caused 
by Trypanosoma evansi. The mice they used for in vivo experiments, however, all turned 
either blue or yellow from the dyes and were not healed from the infection. One of Paul 
Ehrlich’s ideas was to change the structure of one of his dyes to gain better solubility in the 
mice’s blood. Ehrlich called the compound trypan red, a member of the Congo red series of 
cotton dyes, which initially healed the mice infected with T. evansi, but not other 
trypanosomes species [23,24]. Later, the benzopurpurine trypan blue (still used in 
mammalian cell viability assays), provided by the pharmaceutical company Bayer, was found 
to be effective in eliminating all parasites in vivo with a single injection, but still stained the 
mice’s skin bluish as an unacceptable side effect. For this reason, Bayer investigated its 
colorless, but antitrypanosomally active naphthalene derivatives. This resulted in the 
breakthrough discovery of Bayer 205, later renamed as suramin, which is still in use in the 
early stage of the T. b. rhodesiense infection [25]. Because of its sulphuric acid function, 99% 
of suramin binds to the plasma protein albumin. Therefore suramin does not penetrate the 
cerebral fluid, ruling out its use in second stage of disease [26].  
Since the parasites infiltrate the CNS in stage 2, the drug has to cross the BBB to reach the 
parasites. The following two drugs for the second stage infection are recommended by WHO 
(Figure 4).  
Melarsoprol (Arsobal®): 
 In 1905, the Canadian doctor Wolferstan found that the arsenical acid Atoxyl was 
active against trypanosomes in mice [27]. Despite its failure in a trial in East Africa [28] the 
relative success of Atoxyl paved the way for research on arsenicals as chemotherapeutic 
agents for HAT. Thirty years later, Friedheim developed the trivalent arsenic drug 
melarsorpol. Although highly toxic and accompanied by severe side effects – 5-10% of the 
patients develop an encephalopathy of which 50% die [29,30] - the drug is the only option 
against the second stage of T. b. rhodesiense infection [31].  
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Eflornithine (Ornidyl®): 
 Eflornithine, also known as DFMO (α-difluoromethylornithine), was originally 
developed for tumor chemotherapy based on its irreversible ornithine decarboxylase (ODC) 
inhibition, an enzyme involved in polyamine biosynthesis [32,33]. The rapid turnover of the 
mammalian ODC ruled out DFMO as an anticancer drug. In the 80’s, Bacchi cured a T. b. 
brucei infected mouse model with DFMO without any severe side effects. This amazing 
breakthrough lead to several clinical trials followed by a cure in second-stage T. b. 
gambiense infected humans, and its registration in 1990 [34]. A quite interesting recent 
advance in the clinical treatment of HAT has been the combination treatment called NECT 
with orally administered nifurtimox (Lampit®), a nitrofuran derivative developed for the 
treatment of Chagas disease, and intravenously given DFMO for second stage T. b. 
gambiense HAT treatment. The WHO accepted this combination therapy and included it in 
the WHOs list of Essential Medicines in 2009 [35]. Despite DFMO being the only advance in 
the past 25 years in HAT chemotherapy, a clear improvement with reduced toxicity and 
treatment duration has been seen, but the requirement for intravenous administration is still a 
limitation. It is hoped that the broad implementation of the NECT regimen may avert the 
further development of DFMO resistance [36]. 
 
Figure 4. Current treatment options for first and second stage of sleeping sickness disease. 
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1.1.4. Perspectives for the future 
 Only DFMO has been registered in the last 50 years for use against HAT reflecting 
the gap in the drug pipeline. Currently, treatment is still limited in terms of severe side effects 
(e.g. melarsoprol), treatment failures up to 25% [37,38] administration difficulties, expensive 
medication, and lack of drug choice for second stage HAT T. b. rhodesiense. What is 
urgently needed is a safe, orally administered single dose drug, effective against both stages 
of HAT, which then eliminates the need for stage medication and raises the potential for the 
eradication of sleeping sickness disease. In this next section upcoming drug candidates are 
discussed, which are in clinical trials for registration of new chemical entities (NCE) against 
HAT (Figure 5).  
Nitroimidazoles  
 Originally developed by Hoechst as an antimicrobial, fexinidazole, a 2-substituted 5-
nitroimidazole, was shown to be active against trypanosomes in the 1980s, where it 
prevented parasitemic relapses due to CNS infections of T. brucei in mice [39]. However, 
fexinidazole’s development was not pursued at this time. The long forgotten drug was 
rediscovered as a promising candidate due to a screening of more than 700 
nitroheterocyclics against T. brucei. Despite its weaker potency (IC50 of 1.7 μM against T. b. 
rhodesiense) than melarsorpol (IC50 of 0.009 μM against T. b. rhodesiense), but non-specific 
cytotoxicity, the drug cured first stage HAT T. b. rhodesiense and T. b. gambiense infected 
mice with a oral dose of 100 mg/kg/d given for four consecutive days and second stage 
animal model with a oral dose of 100 mg/kg/b.i.d. for five consecutive days [40,41]. Based on 
a full set of preclinical studies conducted in accordance with the regulatory requirements for 
pharmaceuticals for human use, a phase I clinical trial was performed in 2009. In 2012 a 
phase II/III clinical trial was started where patients were treated orally for 10 days with a daily 
single dose [42] in order to register the drug for second stage HAT of both sub-species.  
Benzoxaboroles 
  Scynexis identified a class of boron-containing compounds as novel leads against T. 
brucei [43]. The initial screening revealed SCYX-6759 as the most potent compound with 
BBB permeability. It cured second stage HAT infected mice when they were treated i.p. with 
50 mg/kg/d for 14 consecutive days. At an oral dose of 50 mg/kg/b.i.d. for 7 consecutive days 
it showed a much lower efficacy [44]. Further optimization to improve oral bioavailability was 
done, which brought forward SCYX-7158, a clinical drug candidate with extensiv brain 
exposure using a reduced dose profile with 5 mg/kg for four consecutive days. Toxicity and 
ADME studies were unproblematic [45], which got SCYX-7158 the clearance for a phase I 
clinical trial started in March 2012 [46].  
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Diamidines 
 That aromatic diamidines have trypanocidal potential has been known since the 
development of pentamidine, which is still in use to treat first stage T. b. gambiense. The 
starting point was DB 75 (furamidine) with its prodrug DB289 (pafuramidine) [47,48]. The 
lead showed excellent in vivo efficacy, but lacked 
oral bioavailability in comparison to its prodrug, 
which was the first orally available drug candidate 
for first stage sleeping sickness to enter into 
clinical trials. Unfortunately DB289 had to be 
abandoned due to liver- and nephrotoxicity in 
phase III clinical trials. The diamidine project 
revealed several even more potent diamidines 
than the ones mentioned before: DB868, an aza 
analogue of DB289 cured the second stage HAT 
model and was well tolerated in monkeys [49]. 
Due to lack of financial support and the fact that 
already two other promising clinical candidates in 
the pipeline, the project is currently stopped 
(personal communication, Tanja Wenzler, Swiss 
TPH).  
1.2. Drug discovery from nature 
Considering how difficult it is for a drug to gain 
market approval and how little it takes to kill a drug 
candidate, it is pivotal to keep full drug 
development pipelines and sustain early drug discovery programs. The contemporary 
approach to identifying such compounds is automated high-throughput screening (HTS) of 
large and chemically diverse synthetic compound libraries generated by combinatorial 
chemistry allowing rapid screening and identifying new leads. Sometimes the screening is 
narrowed down by using more targeted libraries that are thought to be enriched with 
compounds with a desired type of activity (e.g. kinase) [50].  
 Another possibility to discover new drugs is to use nature as a potential source. 
Natural products (NP) derived small molecules are still proving to be an invaluable repository 
of medicines for mankind. Newman, Cragg, and Sandler recently analyzed all NCEs that 
enterd the market as registered drugs over the last 30 years [51] and showed that more than 
50% of NCEs were NPs, semi-synthetically produced NP derivatives, or else inspired by 
Figure 5. Drug candidates, which are in the 
clinical trials for registration of new chemical 
entities against HAT. 
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NPs. This reflects the significant influence of nature as source for new drugs. Given that NPs 
have historically provided many novel drugs leads (e.g. khellin, taxol, artemisinin), it might be 
expected that the industry does everything to identify new metabolites from living organisms, 
but instead they have decreased their NP research facilities in the past decades, because 
research on NPs poses several challenges that have to be faced: Hits are likely to have 
complex structures with an abundance of centers of stereochemistry. Secondary metabolites 
are limited in quantity in their organisms of origin due to seasonal or environmental 
variations, which makes the supply of subsequent re-collection difficult. Access to biological 
material is sometimes limited due to the specific geographic growth area. Local botanists, 
which are familiar with the flora of the region to properly identify the origin, are needed. 
Furthermore, species could be endangered and are therefore not allowed to be collected. 
Often, the structures of active compounds will be already known, which makes it impossible 
to file patents [52]. So clearly, drug discovery from nature is problematic. So why should we 
still proceed with drug discovery from nature?  
 Despite of the huge excitement accompanying the introduction of combinatorial 
chemistry, the output of active “hits” of <0.001% among these synthetic compound libraries 
has often been disappointing [53]. In fact, according to Newman’s analysis in 2006 of newly 
approved drugs in the last 25 years only one drug originated from a HTS screen of a 
combinatorial chemistry library [54]. With over a 100 NP derived compounds currently 
undergoing clinical trials and further 100 in preclinical projects it seems that the interest to 
use natural chemical diversity for drug discovery is now growing once again [55]. NPs 
provide a unique chemical diversity created by evolution and cover a broad section of 
chemical space, which is an advantage compared to synthetically produced drugs that can 
be an inspiration for the creation of compounds with improved pharmacological properties. 
There has been a trend to use NP’s privileged scaffolds as the cores for compound libraries 
made by combinatorial chemistry. With this application it becomes possible to create novel 
NP derived structures that can be patented. Furthermore, there have been many recent 
improvements of bioassay guided-fractionation technologies to isolate and purify NPs and 
advances in nuclear magnetic resonance (NMR) and circular dichroism (CD), which make 
drug discovery from nature more efficient [56, 57] and more compatible with HTS drug 
discovery campaigns. 
 Natural sources such as plants have been used as medicines for thousands of years 
and were the first and for a long time the only available source to treat mankind’s diseases. 
With rapid global industrialization a part of the past knowledge will no doubt disappear. 
According to the WHO, 65% of the world’s population still relies on traditional medicines as a 
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primary source of healthcare [58], because they neither have access nor can they afford 
nowadays pharmaceutical medicines. 
1.3. Antiprotozoal drug discovery approach using nature as potential source 
1.3.1. Establishment of extract libraries and antiprotozoal extracts testing  
  The typical process of discovering NP hits starts with the screening of large libraries, 
which themselves may include crude extracts, semi-pure mixtures or purified NPs. Extracts 
may contain many hundreds of compounds belonging to many different biosynthetic classes. 
The choice of the extraction solvent determines the chemical composition of an extract. 
Commonly used solvents are dichloromethane (DCM), hexane, ethyl acetate (EtOAc), and 
methanol (MeOH). Cell based (in vitro) tests are widely used to screen such collections in 
antiprotozoal drug discovery and only a few micrograms of a crude extract are needed to 
perform the bioassays. But also target-based assay or even systems with infected animals 
(in vivo) are commonly used tools.  
 The NP lead discovery projects described in this thesis started with establishing liquid 
extract libraries derived from plants and fungi, of which many were based on traditionally 
used medicines. The plant and fungal material was successively extracted with solvents of 
increasing polarity (n-hexane, EtOAc, MeOH), which yielded a set of three extracts for every 
sample. After drying, the extracts were re-dissolved in dimethylsulfoxide (DMSO; final 
concentration 10 mg/mL) and stored in 2D-barcoded 96-well plates at -80°C. In vitro 
screening of the extract library against the living parasites T. b. rhodesiense, Plasmodium 
falciparum (causative agent of malaria), Leishmania donovani (causative agent of 
leishmaniasis), and T. cruzi (causative agent of Chagas disease) was performed at test 
concentrations of 0.81 μg/mL (low concentration) and 4.81 μg/mL (high concentration) 
Extracts, which showed more than 50% inhibition against one or more parasite at 4.81 μg/mL 
were defined as “hit” and further processed to identify the active ingredients [59,60].  
1.3.2. Isolation and elucidation of natural products from antiprotozoal active plant and 
fungi extracts 
  The most commonly used strategy to identify active NPs from extracts is the 
bioassay-guided isolation. The extracts are fractioned using chromatographic methods such 
as open column chromatography whereas fractions are successively tested in bioassays. 
This approach is time consuming, labor intensive, and expensive [61]. In our laboratory, we 
therefore established a more efficient approach called HPLC-based activity profiling yielding 
a much faster drug discovery platform operating in 96-well plate with high standardization 
and automation. We successfully applied this strategy to find new compounds against the 
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causative agents of protozoal tropical diseases [62]: If an extract had been shown active in 
the initial screening, the extract was separated over an analytical scale HPLC and 
microfractions are collected each minute over 35 min. into a 96-well plate. In parallel 
spectroscopic data (UV, HR-MS, ESI-MS) were gathered. The microfractions in the plate 
were subsequently tested in in vitro bioassays. The overlay of the HPLC chromatogram with 
in vitro activity results from the fractions enabled the identification of the active fractions and 
their constituents. The active compounds were then isolated by semi-preparative and/or 
preparative HPLC after a large scale extraction. Structures were elucidated by 1 and 2-
dimensional NMR spectra. For the assignment of the absolute configuration of the NPs 
circular dichroism (CD) in combination with quantum chemical CD calculations was used. 
Chirality is often a major issue in NP structure elucidation due to their possession of many 
centers of stereochemistry [63]. 
1.3.3. Natural products antiprotozoal in vitro and in vivo evaluation  
 The activity of the isolated compounds was assessed using cell-based proliferation 
assays to determine half maximum inhibition concentrations (IC50s). In parallel, cytotoxicity 
(rat myoblast cells, L6-cell line) assays were done to determine the compounds selectivities. 
These were expressed as the selectivity index (SI; ratio IC50 L6-cells/ parasitic IC50). We 
considered a compound to be a “hit” if it had an IC50 of < 0.2 μg/mL against T. b. rhodesiense 
and P. falciparum with a SI of more than 10. But, even when in vitro SI values were high 
(>100), one can not reasonable extrapolate the toxicity situation to the in vivo model. 
Therefore, in vivo cytotoxicity evaluation is necessary to select a maximal non-toxic 
treatment dose. A cumulative dose of 150 mg/kg i.p. was used to screen pre-toxicity in non-
infected mice. In general, the first experiment to determine in vivo antiprotozoal activity was 
to treat infected mice at a dose of 50 mg/kg/d i.p. for four consecutive days. On day 7 
postinfection a blood smear was done and the parasites were counted. A cure was defined 
when the animal showed no parasites after 60 days postinfection. Due to the efficacy results 
the treatment scheme can be adapted in terms of application route and dose. For modelling 
late stage sleeping sickness the GVR35 mouse CNS model has been established to 
determine a drug’s BBB permeability and CNS efficacy (Figure 6) [64]. 
1.4. Potential of secondary metabolites from nature against antiprotozoal diseases 
 Great efforts have been undertaken over the last decades by numerous research 
groups and many NPs with antiprotozoal activities have been reported in several reviews 
[65-68]. Just recently Schmidt reported about 800 in vitro active antiprotozoal NPs, of which 
32 were tested in animal disease models. In the case of T. brucei 126 NPs were reported to 
have been tested in vitro and 2 in vivo, whereby one compound had shown in vivo 
parasitemia reduction [69, 70]. 
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Our focused in-house liquid extract library, established over the last seven years to find new 
antiprotozoal leads, contains a total of 2151 extracts, which were produced from 724 plants 
and 64 fungi. The in vitro HTS campaign against T. b. rhodesiense, P.falciparum, L. 
donovani, and T. cruzi showed that 17.9% of the extracts had an activity of more than 50% at 
4.81 μg/mL test concentration against at least one parasite and that 3.4% showed potency of 
more than 50% at 0.81 μg/mL test concentration [71-73]. The most active ones were chosen 
to identify the active ingredients by our established HPLC-based activity profiling approach 
[62]. The rapidly follow-up led to 110 isolated compounds of which 13 inhibited T. b. 
rhodesiense and 3 inhibited P. falciparum below 0.5 μM. From these active compounds 
seven were selected as in vivo candidates whereas one NP successfully reduced 
parasitemia in T. b. rhodesiense infected mice (Figure 6) [74-89].  
 Additionally, the most active NPs against T. b. rhodesiense bloodstream forms 
reported in the last years should be mentioned here: Terpinen-4-ol, a terpene with a 
characteristic spicy odor, had an IC50 of 0.02 μg/mL and a SI of > 1000) [69]. This compound 
was however not tested in vivo. Thomas Schmidt and his co-workers published many active 
sesquiterpene lactone (STL) derivatives including helenalin, isolated from Arnica and 
Helenium species, which was one of the most active compounds with an IC50 of 0.051 μM (SI 
19.5). Unfortunately, the STL developed in vivo toxicity and thus led to its failure [90]. In 
2006, a series of 69 flavonoids and flavanoid analogues were tested in vitro and in vivo. The 
most promising hit was 7,8-dihydroxyflavone (IC50 0.068 μM; SI 116), which was chosen for 
in vivo tests. Surprisingly, the compound was assessed in vivo against T. b. brucei instead 
towards T. b. rhodesiense: Infected mice were treated with an i.p. dose of 50 mg/kg/d for four 
consecutive days. Mice had to be euthanized after 13 days postinfection due to increasing 
parasitemia [91]. Another interesting example is the marine alkaloid pyridoacridone, which 
had an IC50 of 7.1 nM (SI >100), which is comparable to the IC50 of the positive control 
melarsoprol (IC50 5 nM). Here too, no in vivo results can be found in databases [92]. But the 
most astonishing IC50 found in the literature was sinefungin, a natural produced nucleoside 
by Streptomyces with IC50 of 0.4 nM and SI more than 106, which was 10 fold more active 
than melarsoprol. Mice infected with T. b. brucei were cured when it was administered i.p., 
but nephrotoxicity in goats blocked any further studies. In vivo studies with T. b. rhodesiense 
infected mice were not done (Figure 7) [93, 94]. 
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In summary, many NPs with potent in vitro antitrypanosomal activity have been reported, for 
which in vivo testing would be 
justified, but in many cases no 
reports on such in vivo studies exist. 
Reasons could be that the isolated 
amount was not sufficient to go on 
with animal tests or in vivo tests 
were performed, but due to a 
negative outcome the results were 
not published. In vitro active 
compounds with lacking in vivo 
activity should not be simply 
abandoned, but instead structural 
modification should be done to 
increase their bioavailability and 
efficacy. Considering the high 
numbers of screened NPs against 
tropical diseases it is astonishing 
that only two made it to the market: 
quinine and artemisinin. Both have 
also been the leads for further semi-
synthetically produced compounds 
against malaria.  
From all these reports it becomes 
evident that further studies to find new lead or drug candidates from nature will be highly 
rewarding.  
 
 
 
 
 
 
 
Figure 7. The most active NPs against T. b. rhodesiense 
bloodstream forms.  
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CHAPTER 2 
Antiprotozoal screening of European macromycetes and 
European plants  
 
First publication: 
The paper highlights the potential of macrofungi for drug discovery by presenting a screen of 
200 extracts against P. falciparum and T. b. rhodesiense. Three fungal extracts had 
determined IC50s below 10 ng/mL making them up to three orders of magnitude lower than 
the most potent plant extracts. These findings were underlined by the truffle Elaphomyces 
granulates in vivo activity when tested at 50 mg/kg/d i.p. for four consecutive days in the T. b. 
rhodesiense acute mouse model where mice remained parasite free for 14 days [1]. 
In vitro testing of the liquid extract library against P. falciparum and T. b. rhodesiense, 
determination of extracts IC50s against P. falciparum, T. b. rhodesiense, and L6-cells 
(cytotoxicity), writing of the manuscript, and preparation of both tables were my contributions 
to this publication. 
Second publication: 
Based on a survey of remedies used in Renaissance Europe to treat malaria, a library of 254 
extracts from 61 plants for in vitro antiplasmodial activity was studied. HPLC-based activity 
profiling of Arctium nemorosum led to the identification of onopordopicrin, a germacranolide 
STL, as a potent inhibitor against P. falciparum (IC50 of 6.9 µM). With an IC50 of 0.37 µM (SI 
8.2) against T. b. rhodesiense was onopordopicrin one of the most potent NPs reported so 
far [2]. 
In vitro testing of the liquid extract library against P. falciparum, HPLC-based activity profiling 
(biological part) of Hyssopus officinalis and Arctium nemorosum, IC50 determination of all 
isolated compounds against P. falciparum, T. b. rhodesiense, and L6-cells (cytotoxicity), 
writing of the manuscript, and preparation of figures (except of Fig. 1 and 4) and tables were 
my contribution to this publication. 
 Stefanie Zimmermann 
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Abstract 
Macrofungi are a rich source of natural products, but have been far less used in drug 
discovery, than higher plants. In this study we explore their antiprotozoal potential in a screen 
of 192 extracts from 64 European macromycete species against the causal agents of 
malaria, human African trypansosomiasis, leishmaniasis, and Chagas disease. Several 
extracts showed very potent and specific antiprotozoal effects. Most noteworthy were the 
extract of Cordyceps ophioglossoides, which inhibited Leishmania donovani with an IC50 of 
30 ng/mL and Plasmodium falciparum with an IC50 of 40 ng/mL. Elaphomyces punctatus was 
active against Trypanosoma brucei rhodesiense (ethyl acetate extract IC50: 20 ng/mL; 
methanol extract IC50: 20 ng/mL) and P.  falciparum (ethyl acetate extract IC50: 30 ng/mL; 
methanol extract IC50: 60 ng/mL). This medium throughput antiprotozoal screen of 
macromycetes demonstrates that the hit rate is similar to the screening results of higher 
plants. The observed potency and selectivity of several fungi extracts was thus three orders 
of magnitude stronger than what is typically observed in plant screens. Macrofungi are an 
underutilized, but very promising source for antiprotozoal drug discovery. 
 
Keywords: 
Macrofungi, screening, Trypanosoma, Plasmodium, Leishmania, antiprotozoal 
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Introduction 
Whilst more than half of our native higher plant flora has been studied phytochemically and 
more than a quarter for biological activities [1], fungi remain a relatively poorly studied source 
of natural products in modern drug discovery. With estimated 1.5 to 5 million species [2, 3] 
fungi outnumber higher plants by at least 16:1, yet only about 100,000 species have been 
taxonomically classified [4]. Macrofungi such as mushrooms, toadstools, puffballs, truffles, 
etc., are fungi that form conspicuous spore-bearing fruiting bodies visible to the naked eye. 
They comprise about 10% of all fungi [5] and their species numbers in temperate regions are 
at least comparable to those of higher plants, but they are less well inventoried. A Swiss 
mushroom field guide [6], for instance, lists 2’486 native species compared to the roughly 
3’000 native taxa of higher plants [7]. Most research on fungal metabolites has been focused 
on a few narrow taxonomic groups within the Ascomycetes, like the genera Penicillium 
(penicillins) or Tolypocladium (cyclosporins), which can be easily cultured. Most slow growing 
or uncultivable groups of fungi, like most macrofungi were never studied [3, 8]. Starting in the 
1940s natural products from terrestrial fungi -alongside other microorganisms- became a 
main focus of the pharmaceutical industry as antibiotics like the penicillins, cephalosporins, 
and polyketides, later followed by many more indications such as the immunosuppressive 
cyclosporins, anti-helmintic ivermectin, as well as the best selling drug of all times the statin 
Lipitor™, developed from the fungal metabolite mevastatin [9].  
In rare cases when mushrooms were chemically studied they provided remarkable lead 
compounds like retapamulin, a semisynthetic derivative of pleuromutilin from the mushroom 
Clitopilus passeckerianus marketed by Glaxo Smith Kline for the topical treatment of skin 
infections [10], irofulvene a derivative of the sesquiterpene illudin from Omphalotus illudens 
[11], currently investigated in clinical trials for prostate, ovarian, and other cancers, or 
strobilurin from the mushroom Strobilurus tenacellus, which led to the development of the 
strobilurine fungicides - now a multi-billion dollar market [12]. Despite being a potential 
treasure trove, macrofungi remain a chemically poorly studied group of organisms. The 
reason for this may lie in their overwhelming taxonomic complexity and ephemerity and 
rareness of sporophore production. Many species are not easily cultivable, largely due to 
highly specialized lifestyles (e.g. mycorrhizal, endophytic, parasitic and other symbiotic 
relationships), and therefore large amounts of fungal matter for chemical investigation are 
hard to obtain. The last decades saw great technological advances in the field of analytics 
and biotesting technologies making it possible to venture deep into areas of biological and 
chemical diversity previously not accessible. Our group has previously establishing 
methodologies, which allow to chemically study larger numbers of samples in smaller 
amounts than ever before, by using technologies like HPLC-based activity profiling to identify 
actives in samples containing just mg amounts [13, 14]. This study is all about harnessing 
 - 25 - 
 
these technological advances to systematically probe mushroom chemodiversity as a source 
of potential antiprotozoal leads. In this study we have ventured into the world of European 
macrofungi to determine whether they are a promising source of potential antiprotozoal 
natural products. We collected wild fungi, established a library of 192 extracts, and screened 
them against the pathogens, which cause malaria, human African trypanosomiasis, 
leishmaniasis, and Chagas disease.  
Each year, every 14th person in the world is infected with malaria and 1-2 million die of it – 
most of them infants [15]. Thirty million people annually contract and 120’000 die of one of 
the protozoan “neglected tropical diseases” [16], which include Chagas disease, human 
African trypanosomiasis, and leishmaniasis [17]. To treat trypanosomatid infections 
(Trypanosoma and Leishmania) there are only few drugs on the market and their 
pharmacological profiles are insufficient by modern standards. These sicknesses have in 
common, that they are all insect borne diseases and strongly linked to poverty. Malaria drugs 
are now reasonably affordable, available and safe, yet few in number and increasingly 
compromised by resistances [18]. New drug leads with new modes of action to combat these 
perils of mankind are urgently needed. 
 
Materials and Methods 
Establishment of a fungal library 
A collection of 64 mushrooms was compiled in September 2011 and identified at a species 
level. Fungal specimens were collected in two Austrian federal states (Styria, Lower Austria) 
in various forest types, mostly in beech-fir-spruce forest and in productions forests dominated 
by spruce. The selection of species was guided both by available material (to ensure that 
sufficient material for extraction be available) and by taxonomy, to represent the phylogenetic 
and ecological diversity of macrofungi as good as possible with a restricted sampling. The 
collection bias towards basidiomycetes is representative of the respective communities of 
fleshy macromycetes. Prior knowledge of medical mushrooms was not used for species 
selection. All fungi were dried in a fungal drying apparatus (Dörrex, SIGG, CH) and voucher 
specimens were deposited at the Department of Pharmaceutical Sciences, University of 
Basel. The voucher numbers are shown in Table S1. For extraction 1 g of sample was used, 
in some cases when not enough material was available as little as 0.28 g was taken. First the 
fungal material was finely ground using a ZM1 ultra centrifugal mill (Retsch; Haan, 
Germany). Powdered material was then successively extracted first with petrol ether, then 
ethyl acetate and finally methanol (all solvents from Scharlau, Barcelona, Spain) using an 
accelerated solvent extraction system ASE (ASE 200, Dionex, Switzerland; 3 cycles at 120 
bar, and 70°C) to give a set of three extracts of increasing polarity for every sample, totalling 
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192 extracts. The extracts were formatted into a library of solutions at 10 mg/ml DMSO in 
three 2D-barcoded 96 well plates, of which three copies were made (Zinsser Analytics, 
France). The plates were stored at –80° C, until use. 
Antiprotozoal screening  
Antiprotozoal screening was repeated twice at 0.8 and 4.8 µg/mL. The most active extracts 
were tested in serial dilution in two independent assays to determine their 50% inhibitory 
concentration (IC50).  
Protozoan parasites and cell line 
Trypanosoma brucei rhodesiense (STIB 900) were grown in Minimum Essential Medium 
(MEM) with Earle’s salts supplemented with 0.2 mM 2-mercaptoethanol as described by 
Baltz et al. [19] with the following modifications: 1 mM sodium pyruvate, 0.5 mM 
hypoxanthine, and 15% heat-inactivated horse serum. Cultures were maintained in a 
humidified 5% CO2 atmosphere at 37 °C. Trypanosoma cruzi trypomastigote forms 
(Tulahuen strain C2C4 containing the β-galactosidase (Lac Z) gene) were cultured in RPMI 
1640 medium supplement with 10% fetal bovine serum and 2 mM L-glutamine [20] and 
maintained in a humidified 5% CO2 atmosphere at 37 °C. Antiplasmodial activity was 
determined against the chloroquine- and pyrimethamine-resistant Plasmodium falciparum K1 
strain. The parasites were maintained by the method of [21] in a humidified atmosphere 
consisting of 4% CO2, 3% O2, and 93 % N2 at 37 °C. Rat skeletal myoblast cells (L6-cells) 
were seeded in RPMI 1640 medium supplemented with 2 µM L-glutamine, 5.95 g/L HEPES, 
2 g/L NaHCO3  and 10% fetal bovine serum as previously reported [13]. The cultures were 
routinely maintained by weekly passages at 37 °C under a humidified 5% CO2 atmosphere. 
Bioassays 
Trypanosoma brucei rhodesiense (STIB 900 strain) bioassay 
Evaluation of in vitro antiprotozoal activity against T. b. rhodesiense was done using the 
Alamar Blue assay to determine IC50s as previously described [22]. Serial threefold dilution 
were prepared in 96-well micro titer plates and 2000 T. b. rhodesiense STIB 900 
bloodstream forms in 50 μL were added to each well except for the negative controls. 
Melarsoprol (Arsobal®, purity> 95%, Sanofi-Aventis, Meyrin, Switzerland) was used as 
reference drug. After 70 h of incubation 10 μL of Alamar blue marker (12.5 mg resazurin 
(Sigma-Aldrich, Buchs, Switzerland) dissolved in 100 mL of distilled water) was added, and 
color change was developed for 2 to 6 h. A Spectramax Gemini XS micro plate fluorescence 
reader (Molecular Devices Cooperation, Sunnyvale, CA) with an excitation wavelength of 
536 nm and an emission wavelength of 588 nm was used to read the plates. The IC50 values 
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were calculated from the sigmoidal growth inhibition curves using Softmax Pro software 
(Molecular Devices).  
Trypanosoma cruzi bioassay 
In vitro testing against T. cruzi: Rat skeletal myoblasts (L-6 cells) were seeded in 96-well 
microtitre plates at 2000 cells/well in 100 μL RPMI 1640 medium. After 24 h the medium was 
removed and replaced by 100 μL containing 5000 trypomastigote forms of T. cruzi. After 48 h 
the medium was removed and replaced by 100 μL of fresh medium with the serial threefold 
drug dilutions. The plates were incubated under a humidified 5% CO2 atmosphere at 37°C for 
an additional 96 h. Then chlorophenyl red β-D-galactopyranoside agent (CPRG)/Nonident 
(50 μL) (Sigma-Aldrich) was added to all wells and a color change was developed within 2 to 
6 h. The plates were read photometrically at 540 nm. Data were evaluated and IC50 values 
calculated with Softmax Pro software (Molecular Devices) [20]. Benznidazole (purity > 95%, 
Sigma-Aldrich) was used as a standard drug. 
Plasmodium falciparum bioassay 
In vitro testing against P. falciparum: Antiplasmodial activity was determined with the [3H]-
hypoxanthine incorporation assay [23]. Chloroquine (purity > 95%, Sigma-Aldrich) and 
artesunate (purity > 95%, Mepha, Switzerland) were used as standard drugs. Briefly, infected 
human red blood cells (final parasitemia and hematocrit were 0.3% and 1.25%, respectively) 
in RPMI 1640 medium were exposed to twofold serial drug dilutions in 96-well micro titer 
plates. After 48 h of incubation, 50 μL of [3H]-hypoxanthine (0.5 μCi) were added to each 
well. The plates were incubated for further 24 h before being harvested using a Betaplate cell 
harvester (Wallac, Zürich, Switzerland) onto glass-fiber filters and then washed with distilled 
water. The dried filters were inserted into plastic foils with 10 mL scintillation fluid. The 
radioactivity was counted with a Betaplate liquid scintillation counter (Wallac) as counts per 
minute per well at each drug concentration and compared to the untreated controls. IC50 
values were calculated from sigmoidal inhibition curve. 
Rat myoblast cell L6-cytotoxicity assay 
The cytotoxicity assay was performed using the Alamar Blue assay [22] described above 
with rat skeletal myoblasts (L6-cells)  seeded in 100 μL RPMI 1640 in 96-well micro titer 
plates. After 24 h the medium was removed and replaced by 100 μL of fresh RPMI 1640 with 
or without a serial threefold drug dilution. Podophyllotoxin (purity > 95%, Sigma-Aldrich) was 
used as the reference drug. After 70 h of incubation under a humidified 5% CO2 atmosphere, 
10 μL of the Alamar blue marker (see above) was added to all wells. The plates were 
incubated for an additional 2 h. A Spectramax Gemini XS micro plate fluorescence reader 
(Molecular Devices) was used to read the plates using an excitation wavelength of 536 nm 
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and an emission wavelength of 588 nm. The IC50s were calculated from the sigmoidal growth 
inhibition curves using Softmax Pro software (Molecular Devices). 
Acute mouse sleeping sickness model 
This model mimics the first stage of the human African trypanosmiasis. Adult female NMRI 
mice were purchased from Janvier (St. Berthevin, France). They weighed between 20 and 25 
g at the beginning of the study and were kept under standard conditions in macrolon type III 
cages with food pellets and water ad libitum at 22 °C and 60-70% humidity. All protocols and 
procedures used in this study were reviewed and approved by the local veterinary authorities 
of the Canton Basel-Stadt, Switzerland (authorization N° 739; 11.12.2009). The samples 
were first dissolved in 100% DMSO followed by addition of distilled H2O to a final DMSO 
concentration of 10%. For the establishment of the in vivo antitrypanosomal activity, the mice 
were infected intraperitoneally with 1 x 104 STIB900 bloodstream forms. Experimental groups 
of four mice were treated orally once a day on four consecutive days from day 3 to day 6 
post infection. A control group of four mice was infected, but remained untreated. The 
determination of the parasitemia was done on day 7 post infection. Six μL of tail blood were 
diluted in 24 μL sodium citrate (3.2%), whereby the first μL was discarded to obtain 
circulating blood. Five μL of this mixture were transferred to a glass slide and covered with 
an 18 x 18 mm cover slide. The sample was examined under a light microscope (200-fold 
magnification) and parasites were counted in 3 of the 16 squares of the grid. 
Results and Discussion  
A total of 192 extracts, which represent three extracts of different polarity (petrol ether, ethyl 
acetate, and methanol) from different 64 fungi were screened against the protozoan 
parasites that cause malaria, human African trypanosomiasis, Chagas disease, and 
leishmaniasis. The results of the fungal extract screening (Table S1) showed two extracts 
from one fungus (Elaphomyces granulates) with a 100% inhibition at the lower test 
concentration against T. brucei rhodesiense. Pycnoporus cinnabarinus showed 77% 
inhibition of P. falciparum at the higher concentration and Elaphomyces granulates indicated 
a 75% inhibition of P. falciparum at the higher concentration. The most promising extracts 
Cordyceps ophioglossoides (EtOAc extract), Elaphomyces granulates (EtOAc and MeOH 
extract), and Pycnoporus cinnabarinus (EtOAc and MeOH extract) were tested and IC50 were 
determined against T. b. rhodesisense, P.falciparum, L. donovani, und T. cruzi. Additionally, 
cytotoxicities against rodent cell line were established to show their selectivity toward the 
protozoan parasites. None of these active extracts were generally toxic towards the rodent 
cell line and the cytotoxic effects were moderate with selectivities of more than 100 in the 
case of Elaphomyces granulatus. With the next step we study the extracts by HPLC-based 
activity profiling to isolate and identify their active constituents. 
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Our research collaboration has in recent years been involved in the screening of many 
thousand plant extracts against protozoan parasites and the subsequent identification of 
active natural products from them [24-33]. 
Hereby we have learned that in these screening systems the test concentration of 4.81 
µg/mL were a stringent selection criteria to identify just a small percentage of samples (< 5%) 
as actives. At the six-fold dilution (0.81 µg/mL) only very few of these would be promising. 
Applying these filters of defining actives, this screen of European macrofungi shows a similar 
“hit rate” as many screens of plant extract libraries [34] with 2 out of 64 samples (3.1%) 
showing total inhibition of at least one parasite at the lower screen concentration. What really 
puts the fungi in a class of their own though, is that the few actives showed astonishing 
activities and selectivities. Several active extracts showed IC50s below 60 ng/mL (Table 1) 
and that they were up to three orders of magnitude stronger than anything we had 
experienced with plant extracts.  
These results were supported by in vivo antitrypanosomal activity of the Elaphomyces EtOAc 
extract when mice were treated ip with 50 mg/kg/body weight/day for four consecutive days. 
In comparison to the control group, which were euthanized after a week, were treated mice 
parasite-free for 14 days postinfection.  
It is noteworthy that this screen did not detect generally toxic fungi as in fact Elaphomyces is 
regarded as non toxic or even edible when cooked [35]. This study suggests that extracts of 
macrofungi can show antiparasitic effects more potent than the far better studied plant 
extracts and the relative frequency of this could be similar or higher than for plant extracts. 
This study is the starting point for a chemical study of the most promising fungi to identify 
their active constituents. 
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Table 1 Antiprotozoal effects (IC50 in µg/mL ± standard of the mean SD) of 5 selected 
extracts against the 4 protozoal parasites T.b.rhodesisense, T. cruzi, L. donovani, and P. 
falciparum, as well as the cytotoxic effects against rat myoblast (L6) cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
extract 
Extract 
solvent 
T.b. 
rhodesiense 
T. cruzi L. donovani 
P. 
falciparum 
L6 
Cordyceps 
ophioglossoides 
EtOAc 1.1 ± 0.1 5.7 ± 8.6 0.03 ± 0.01 0.4 ± 0.02 3.8 ± 0.4 
Elaphomyces 
granulatus 
EtOAc 0.02 ± 0.001 4.8 ± 1.0 0.3 ± 0.1 0.03 ± 0.03 > 20 
Elaphomyces 
granulatus 
MeOH 0.02 ± 0.001 8.6 ± 0.01 1.2 ± 0.1 0.06 ± 0.04 > 20 
Pycnoporus 
cinnabarinus 
EtOAc 5.9 ± 2.3 9.6 ± 0.1 2.8 ± 0.8 1.7 ± 0.06 2.6 ± 1.3 
Pycnoporus 
cinnabarinus 
MeOH 4.0 ± 0.3 7.7 ± 3.6 2.1 ± 1.0 1.6 ± 0.2 1.1 ± 0.1 
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Table S1 Antiplasmodial and antitrypanosomal activity (growth inhibition in % ± standard of 
the mean SD) of 196 fungal extracts against STIB 900 strain and Plasmodium falciparum 
(K1) strain. Bioassays were carried out in two independent experiments, at test 
concentrations of 4.81 (higher concentration= HC) µg/mL and 0.81 µg/mL (lower 
concentration= LC), respectively. The positive control was artesunate (100% inhibition in all 
bioassays) and melarsoprol. 
   T.b. rhodesiense STIB 900 P. falciparum K1 
Species Extract solvent 
Organism 
number 
HC ± SD LC ± SD HC ± SD LC ± SD 
Boletus radicans Pers. 
PE MM001 6.5 ± 9.2 10.6 ± 3.9 21.1 ± 9.1 24.3 ± 6.9 
EtOAC MM001 10.2 ± 4.5 5.4 ± 7.6 21.1 ± 0.0 33.2 ± 17.5 
MeOH MM001 9.8 ± 6.3 9.9 ± 2.2 24.3 ± 16.1 14.2 ± 10.6 
Flammulina velutipes (Curtis) Singer 
PE MM002 4.2 ± 2.1 7.1 ± 4.7 17.0 ± 10.5 13.5 ± 2.8 
EtOAC MM002 4.6 ± 6.4 3.0 ± 1.8 6.6 ± 1.1 13.0 ± 10.5 
MeOH MM002 6.4 ± 5.3 10.6 ± 2.0 15.2 ± 9.0 0.4 ± 0.6 
Piptoporus betulinus (Bull.) P. Karst 
PE MM003 6.9 ± 4.0 1.6 ± 2.2 13.0 ± 7.0 15.0 ± 2.1 
EtOAC MM003 1.5 ± 2.1 1.8 ± 2.5 34.4 ± 10.8 7.8 ± 7.1 
MeOH MM003 8.7 ± 12.3 5.6 ± 7.9 21.2 ± 19.5 23.1 ± 9.3 
Lactarius vellereus (Fr.) Fr 
PE MM004 9.5 ± 7.1 10.2 ± 4.0 26.4 ± 11.2 18.0 ± 2.7 
EtOAC MM004 11.5 ± 11.6 7.8 ± 10.4 28.0 ± 11.4 17.2 ± 7.3 
MeOH MM004 6.5 ± 9.1 0.0 ± 0.0 23.6 ± 10.1 2.4 ± 1.6 
Russula badia Quél. 
PE MM005 6.2 ± 8.8 2.9 ± 1.6 16.0 ± 20.0 23.9 ± 2.1 
EtOAC MM005 4.9 ± 6.9 1.3 ± 1.8 23.1 ± 7.6 13.5 ± 1.5 
MeOH MM005 6.9 ± 4.7 0.0 ± 0.0 13.8 ± 13.6 8.5 ± 12.0 
Amanita citrina (Schaeff.) Pers. 
PE MM006 4.8 ± 6.8 0.0 ± 0.0 17.7 ± 6.1 1.8 ± 2.5 
EtOAC MM006 2.3 ± 3.2 2.6 ± 3.7 2.0 ± 2.8 4.4 ± 0.5 
MeOH MM006 0.0 ± 0.0 0.0 ± 0.0 19.8 ± 13.9 5.6 ± 1.9 
Amanita muscaria (L.) Lam. 
PE MM007 0.0 ± 0.0 2.7 ± 3.8 9.4 ± 1.8 0.7 ± 1.0 
EtOAC MM007 7.0 ± 9.9 4.1 ± 5.7 19.0 ± 11.1 14.1 ± 4.1 
MeOH MM007 3.4 ± 4.8 3.1 ± 4.3 16.1 ± 14.3 16.9 ± 6.7 
Hygrocybe virginea (Wulfen) P.D. Orton 
& Watling 
PE MM008 7.9 ± 5.9 3.2 ± 4.5 28.4 ± 3.3 12.8 ± 13.5 
EtOAC MM008 4.4 ± 6.2 0.0 ± 0.0 19.1 ± 5.2  9.5 ± 5.0 
MeOH MM008 0.0 ± 0.0 1.1 ± 1.6 12.8 ± 1.9 37.0 ± 6.1 
Hygrocybe psittacina (Schaeff.) P. Kumm. 
PE MM009 3.7 ± 5.2 3.9 ± 1.7 8.0 ± 3.9 7.3 ± 10.3 
EtOAC MM009 2.0 ± 1.5 0.8 ± 1.1 1.9 ± 2.7 1.6 ± 2.2 
MeOH MM009 0.0 ± 0.0 1.1 ± 1.6 15.0 ± 4.1 4.6 ± 6.5 
Lactarius semisanguifluus R. Heim & 
Leclair 
PE MM010 0.0 ± 0.0 0.0 ± 0.0 17.6 ± 5.5 2.2 ± 3.1 
EtOAC MM010 0.0 ± 0.0 0.0 ± 0.0 20.8 ± 4.0 0.3 ± 0.4 
MeOH MM010 0.0 ± 0.0 3.6 ± 5.1 14.6 ± 7.5 0.0 ± 0.0 
 - 36 - 
 
Hygrobe conica (Schaeff.) P. Kumm. 
PE MM011 2.8 ± 4.0 4.1 ± 4.5 18.1 ± 15.6 10.6 ± 0.5 
EtOAC MM011 0.3 ± 0.4 4.5 ± 6.3 14.9 ± 5.4 5.3 ± 7.1 
MeOH MM011 7.5 ± 2.8 3.5 ± 2.8 17.2 ± 2.7 8.9 ± 2.9 
Chroogomphus rutilus (Schaeff.: Fr.) O.K. 
Mill. 
PE MM012 21.9 ± 5.6 8.7 ± 4.4 17.2 ± 14.6 8.9 ± 5.0 
EtOAC MM012 8.0 ± 11.2 2.2 ± 3.1 19.3 ± 8.9 1.3 ± 1.8 
MeOH MM012 9.0 ± 2.8 6.9 ± 4.5 15.9 ± 17.0 3.5 ± 5.0 
Scleroderma citrinum Pers. 
PE MM013 0.9 ± 1.2 1.4 ± 1.9 15.9 ± 9.4 5.0 ± 7.1 
EtOAC MM013 0.8 ± 1.1 0.0 ± 0.0 34.9 ± 13.7 5.4 ± 2.3 
MeOH MM013 0.0 ± 0.0 0.6 ± 0.8 11.2 ± 10.1 2.0 ± 0.9 
Xerocomus badius (Pers.) E.-J. Gilbert 
PE MM014 2.6 ± 2.5 2.4 ± 3.4 13.9 ± 7.4 4.0 ± 0.4 
EtOAC MM014 1.3 ± 1.8  1.0 ± 1.3 9.4 ± 6.3 2.9 ± 4.1 
MeOH MM014 6.1 ± 8.6 2.9 ± 1.3 19.8 ± 8.6 12.3 ± 0.4 
Xerocomus chrysenteron (Bull.)  Quel. 
PE MM015 0.3 ± 0.4 6.4 ± 0.1 18.5 ± 17.3 7.0 ± 0.9 
EtOAC MM015 6.8 ± 6.6 3.7 ± 5.2 25.6 ± 13.2 8.7 ± 4.9 
MeOH MM015 5.1 ± 4.7 1.0 ± 1.3 16.7 ± 1.7 3.9 ± 5.0 
Chalciporus piperatus (Bull.) Bataille 
PE MM016 5.2 ± 4.3 5.7 ± 0.5 18.5 ± 9.8 9.0 ± 12.7 
EtOAC MM016 17.8 ± 10.0 0.0 ± 0.0 29.4 ± 13.7 5.9 ± 1.5 
MeOH MM016 6.2 ± 0.1 3.1 ± 4.3 10.7 ± 15.1 0.3 ± 0.4 
Leccinum scabrum var. melaneum  
(Smotl.) Dermek 
PE MM017 0.0 ± 0.0 0.0 ± 0.0 7.0 ± 2.2 3.8 ± 4.3 
EtOAC MM017 0.0 ± 0.0  4.2 ± 5.9 14.5 ± 11.5 2.3 ± 3.2 
MeOH MM017 2.8 ± 0.4 2.4 ± 3.4 15.7 ± 7.0 0.0 ± 0.0 
Leccinum versipelle (Fr. & Hök) Snell 
PE MM018 1.8 ± 2.5 0.0 ± 0.0 9.6 ± 4.9 0.7 ± 1.0 
EtOAC MM018 5.8 ± 8.1 1.8 ± 0.8 25.4 ± 7.4 8.8 ± 5.3 
MeOH MM018 0.0 ± 0.0 2.5 ± 3.5 17.2 ± 12.7 0.0 ± 0.0 
Leccinum brunneogriseolum Lannoy & 
Estadès 
PE MM019 9.4 ± 1.8 2.7 ± 1.4 21.1 ± 4.7 15.5 ± 8.8 
EtOAC MM019 3.7 ± 5.2 4.8 ± 6.7 21.2 ± 4.7 8.2 ± 10.8 
MeOH MM019 2.6 ± 2.6 0.9 ± 0.9 16.5 ± 13.3 1.6 ± 2.2 
Paxillus involutus (Batsch) Fr. 
PE MM020 3.5 ± 4.9 6.0 ± 2.5 13.7 ± 10.3 3.5 ± 5.0 
EtOAC MM020 0.0 ± 0.0 4.4 ± 6.2 30.2 ± 27.5 1.8 ± 2.6 
MeOH MM020 0.0 ± 0.0 0.0 ± 0.0 21.0 ± 4.6 10.8 ± 2.6 
Hydrophobus agathosmus (Fr.) Fr. 
PE MM021 0.0 ± 0.0 1.5 ± 2.1 20.3 ± 7.4 1.9 ± 2.6 
EtOAC MM021 1.3 ± 1.8 2.8 ± 4.0 15.0 ± 11.0 7.2 ± 1.4 
MeOH MM021 0.1 ± 0.1 1.4 ± 2.0 6.1 ± 1.1 0.0 ± 0.0 
Lactarius turpis (Weinm.) Fr.  
PE MM022 2.2 ± 3.0 5.1 ± 7.2 28.4 ± 3.6 19.4 ± 4.2 
EtOAC MM022 0.0 ± 0.0 3.1 ± 4.3 17.7 ± 3.6 2.3 ± 2.6 
MeOH MM022 4.4 ± 6.2 2.1 ± 1.9 16.4 ± 1.8 14.4 ± 10.3 
Lactarius glyciosmus (Fr.) Fr. 
PE MM023 9.3 ± 3.1 6.9 ± 2.2 21.1 ± 2.1 9.9 ± 3.7 
EtOAC MM023 6.2 ± 4.1 6.7 ± 5.2 19.9 ± 10.7 3.5 ± 1.1 
MeOH MM023 7.9 ± 1.0 3.0 ± 1.8 21.8 ± 10.0 6.6 ± 2.3 
Macrocysridia cucumis (Pers.) Joss. PE MM024 0.8 ± 1.1 5.0 ± 7.0 17.1 ± 10.5 2.6 ± 3.6 
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EtOAC MM024 0.0 ± 0.0 0.1 ± 0.1 16.2 ± 6.5 3.9 ± 0.6 
MeOH MM024 0.0 ± 0.0 2.0 ± 2.8 26.2 ± 1.2 6.7 ± 9.4 
Tricholoma cf. fulvum (Fr.) Bigeard & H. 
Guill. 
PE MM025 0.0 ± 0.0 2.2 ± 3.1 21.1 ± 7.9 15.2 ± 0.1 
EtOAC MM025 4.1± 5.7 4.7 ± 6.6 12.8 ± 9.2 1.0 ± 0.9 
MeOH MM025 5.8 ± 4.0 1.0 ± 1.3 23.7 ± 10.0 15.4 ± 15.3 
Clitopilus prunulus (Scop. ) P. Kumm PE MM026 3.7 ± 5.0 2.7 ± 3.8 18.3 ± 2.8 13.7 ± 10.5 
Clitopilus prunulus (Scop. ) P. Kumm 
EtOAC MM026 2.8 ± 3.4 0.3 ± 0.4 17.6 ± 9.3 12.1 ± 16.5 
MeOH MM026 12.5 ± 5.2 5.3 ± 0.1 26.9 ± 12.8 16.8 ± 2.3 
Climacocystis borealis (Fr.) Kotl. & Pouzar 
PE MM027 2.7 ± 3.7 6.1 ± 0.9 29.3 ± 5.9 12.1 ± 12.1 
EtOAC MM027 11.6 ± 3.0 0.0 ± 0.0 20.5 ± 8.2 11.9 ± 4.4 
MeOH MM027 14.4 ± 5.1 6.6 ± 7.1 30.2 ± 4.2 13.1 ± 1.6 
Cortinarius bolaris (Pers.) Fr. 
PE MM028 8.8 ± 2.1 4.3 ± 0.9 16.6 ± 0.8 8.4 ± 2.8 
EtOAC MM028 7.1 ± 0.9 4.7 ± 6.6 22.4 ± 0.1 0.8 ± 1.1 
MeOH MM028 14.6 ± 9.0 5.1 ± 2.8 14.1 ± 2.0 6.8 ± 6.2 
Mycetinis alliaceus (Jacq.) Earle ex A.W. 
Wilson & Desjardin 
PE MM029 3.8 ± 5.3 7.5 ± 4.0 17.5 ± 5.5 5.0 ± 1.3 
EtOAC MM029 11.9 ± 3.4 4.9 ± 3.0 24.2 ± 9.3 14.1 ± 6.0 
MeOH MM029 3.4 ± 1.8 3.4 ± 1.1 28.8 ± 1.7 9.1 ± 2.9 
Clitocybula lacerata  (Scop.) Singer ex 
Métrod 
PE MM030 15.2 ± 9.2 19.4 ± 16.3 27.2 ± 11.5 29.0 ± 7.2 
EtOAC MM030 19.1 ± 14.2 13.0 ± 11.0 34.9 ± 13.5 16.2 ± 17.3 
MeOH MM030 17.2 ± 17.6  16.3 ± 17.7 33.0 ± 18.0 19.1 ± 7.1 
Hydnum repandum L. 
PE MM031 15.0 ± 10.1 13.0 ± 7.8 32.1 ± 20.2 25.7 ± 16.7 
EtOAC MM031 11.2 ± 8.2 3.3 ± 4.6 7.7 ± 10.8 7.1 ± 10.0 
MeOH MM031 13.3 ± 18.8 7.4 ± 10.4 25.9 ± 12.0 12.3 ± 15.2 
Fomitopsis pinicola (Sw.) P. Karst. 
PE MM032 7.8 ± 11.0 0.8 ± 1.1 28.4 ± 16.7 4.4 ± 6.2 
EtOAC MM032 3.6 ± 5.0 3.9 ± 5.5 34.6 ± 0.5 6.9 ± 3.5 
MeOH MM032 8.2 ± 10.3 8.4 ± 9.8 30.4 ± 6.8 23.3 ± 12.7 
Pycnoporus cinnabarinus (Jacq.) P. Karst 
PE MM033 9.6 ± 12.2 7.7 ± 10.8 27.2 ± 13.6 5.6 ± 7.9 
EtOAC MM033 10.3 ± 14.6 4.3 ± 6.0 68.2 ± 5.2 14.5 ± 11.5 
MeOH MM033 30.5 ± 26.4 7.2 ± 10.1 77.2 ± 16.7 22.7 ± 13.2 
 Russula densifolia Secr. Ex Gillet 
PE MM034 5.6 ± 7.9 0.0 ± 0.0 20.8 ± 18.5 16.8 ± 14.1 
EtOAC MM034 1.0 ± 1.3 2.2 ± 3.0 34.9 ± 17.6 22.8 ± 17.4 
MeOH MM034 1.1 ± 1.6 2.3 ± 3.3 30.0 ± 13.9 21.3 ± 13.3 
Pleurocybella porrigens (Pers.) Singer 
PE MM035 6.8 ± 9.6 7.0 ± 4.7 19.3 ± 3.0 9.0 ± 3.9 
EtOAC MM035 13.4 ± 12.2 5.6 ± 7.8 25.8 ± 24.7 2.1 ± 3.0 
MeOH MM035 8.9 ± 12.5 7.5 ± 10.5 16.1 ± 5.8 12.8 ± 3.2 
Porphyrellus porphyrosporus (Fr. & Hök) 
E.-J. Gilbert 
PE MM036 5.8 ± 8.2 0.6 ± 0.8 21.4 ± 11.8 9.3 ± 3.3 
EtOAC MM036 10.3 ± 8.9 8.1 ± 1.0 22.2 ± 7.3 9.2 ± 13.0 
MeOH MM036 9.9 ± 6.4 8.2 ± 4.9 14.9 ± 4.8 10.8 ± 15.2 
Russula cavipes Britzelm. 
PE MM037 10.4 ± 5.3 5.5 ± 1.2 30.5 ± 0.4 15.4 ± 13.2 
EtOAC MM037 4.9 ± 6.9 4.5 ± 2.5 25.9 ± 9.2 18.9 ± 11.4 
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 MeOH MM037 0.0 ± 0.0 1.3 ± 1.8 25.0 ± 13.9 16.3 ± 7.9 
Lactarius salmonicolor R. Heim & Leclair 
PE MM038 4.0 ± 5.6 2.0 ± 2.8 26.3 ± 10.5 10.9 ± 15.3 
EtOAC MM038 0.2 ± 0.2 1.9 ± 2.6 20.4 ± 15.9 13.1 ± 11.2 
MeOH MM038 5.8 ± 8.2 3.4 ± 4.7 14.6 ± 2.6 10.8 ± 5.6 
Tricholomopsis decora (Fr.) Singer 
PE MM039 5.4 ± 4.7 2.2 ± 3.0 15.3 ± 3.3 0.0 ± 0.0 
EtOAC MM039 2.8 ± 4.0 1.1 ± 1.6 15.1 ± 7.1 13.6 ± 12.5 
MeOH MM039 0.0 ± 0.0 6.2 ± 8.8 10.9 ± 2.3 0.0 ± 0.0 
Tricholoma sciodes (Pers.) C. Martín 
PE MM040 8.9 ± 6.1 3.7 ± 3.3 25.4 ± 2.8 10.8 ± 7.4 
EtOAC MM040 4.3 ± 6.0 1.7 ± 2.4 24.9 ± 11.7 5.9 ± 8.3 
Tricholoma sciodes (Pers.) C. Martín MeOH MM040 7.7 ± 5.6 4.1 ± 4.5 10.2 ± 0.5 1.2 ± 1.6 
Amanita submembranaceae (Bon) 
Gröger 
PE MM041 2.4 ± 3.4 7.5 ± 0.1 28.2 ± 15.2  18.4 ± 8.7 
EtOAC MM041 3.0 ± 2.3 9.8 ± 0.5 24.9 ± 24.8 17.4 ± 11.3 
MeOH MM041 3.6 ± 1.9 2.1 ± 2.9 20.1 ± 14.9 22.0 ± 16.4 
Inocybe cervicolor (Pers.) Quél. 
PE MM042 3.8 ± 5.4 8.7 ± 6.4 22.8 ± 24.9 11.6 ± 16.3 
EtOAC MM042 2.5 ± 3.5 3.3 ± 4.7 11.6 ± 6.9 6.7 ± 0.7 
MeOH MM042 6.1 ± 8.6 4.3 ± 6.1 15.2 ± 1.6 3.1 ± 4.4 
Inocybe corydalina Quél. 
PE MM043 11.5 ± 1.0 2.9 ± 2.6 5.3 ± 6.9 4.9 ± 6.9 
EtOAC MM043 0.7 ± 0.9 0.0 ± 0.0 16.3 ± 13.4 1.0 ± 1.4 
MeOH MM043 3.6 ± 5.1 3.0 ± 4.2 29.2 ± 2.2 15.8 ± 0.1 
Hypomyces viridis (Alb. & Schwein.) P. 
Karst.  on Russula spec. 
PE MM044 5.6 ± 7.9 6.8 ± 1.8 22.9 ± 2.1 6.7 ± 9.4 
EtOAC MM044 5.1 ± 6.8 4.6 ± 0.8 17.6 ± 0.8 10.2 ± 5.9 
MeOH MM044 0.0 ± 0.0 0.0 ± 0.0 25.2 ± 12.0 9.8 ± 13.8 
Thelephora palmata (Scop.) Fr. 
PE MM045 0.5 ± 0.6 2.8 ± 2.6 19.7 ± 16.2 13.9 ± 19.6 
EtOAC MM045 4.0 ± 5.7 0.0 ± 0.0 17.4 ± 9.2 9.1 ± 10.5 
MeOH MM045 2.9 ± 4.0 3.1 ± 4.4 21.7 ± 23.3 11.0 ± 15.5 
Hydnellum peckii Banker 
PE MM046 7.4 ± 10.4 2.6 ± 3.7 11.0 ±15.6 1.5 ± 2.1 
EtOAC MM046 8.6 ± 12.1 5.9 ± 8.3 17.7 ± 0.1 0.0 ± 0.0 
MeOH MM046 11.8 ± 16.6 6.3 ± 0.8 11.8 ± 0.4 2.3 ± 3.2 
Cantharellus lutescens (Pers.) Fr. 
PE MM047 0.2 ± 0.3 0.0 ± 0.0 24.6 ± 8.6 17.4 ± 8.2 
EtOAC MM047 2.2 ± 3.1 3.8 ± 5.3 32.2 ± 0.3 10.9 ± 5.9 
MeOH MM047 1.6 ± 2.2 1.9 ± 2.5 15.2 ± 1.1 15.8 ± 15.9 
Craterellus tubaeformis (Fr.) Quél. 
PE MM048 6.5 ± 9.2 3.6 ± 0.9 17.2 ± 9.1 12.6 ± 6.3 
EtOAC MM048 0.5 ± 0.7 0.0 ± 0.0 26.8 ± 5.6  14.8 ± 7.9 
MeOH MM048 0.0 ± 0.0 0.0 ± 0.0 18.9 ± 16.2 7.3 ± 10.3 
Hydnellum concrescens (Pers.) Banker 
PE MM049 0.0 ± 0.0 1.8 ± 2.5 22.1 ± 11.8 19.0 ± 12.8 
EtOAC MM049 3.4 ± 3.0 2.2 ± 3.1 22.2 ± 18.7 13.4 ± 18.8 
MeOH MM049 11.7 ± 16.5 5.5 ± 7.7 14.8 ± 7.4 0.0 ± 0.0 
Sarcodon imbricatum (L.) P. Karst. 
PE MM050 3.8 ± 5.3 1.7 ± 2.4 8.7 ± 0.5 1.9 ± 2.6 
EtOAC MM050 3.6 ± 5.0 1.2 ± 1.6 18.9 ± 4.9 2.5 ± 3.5 
MeOH MM050 0.9 ± 1.2 0.0 ± 0.0 6.9 ± 8.0 0.0 ± 0.0 
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Boletopsis leucomelaena (Pers) Fayod 
PE MM051 5.8 ± 4.2 2.5 ± 1.2 25.2 ± 9.2 12.9 ± 2.1 
EtOAC MM051 5.3 ± 7.4 5.5 ± 0.3 17.8 ± 0.6 2.5 ± 3.0 
MeOH MM051 8.3 ± 10.0 5.3 ± 3.3 20.6 ± 0.7 6.8 ± 2.7 
Gloeophyllum sepiarium  (Wulfen) P. 
Karst. 
PE MM052 0.0 ± 0.0 0.1 ± 0.1 27.9 ± 2.8 21.7 ± 2.2 
EtOAC MM052 0.0 ± 0.0 0.5 ± 0.6 25.2 ± 14.0 14.9 ± 7.5 
MeOH MM052 1.5 ± 2.1 1.8 ± 2.5 25.1 ± 16.6 23.5 ± 4.7 
Clavulina cristata (Holmsk.) J. Schröt. 
PE MM053 4.1 ± 2.0 7.2 ± 0.2 25.8 ± 21.5 14.5 ± 18.7 
EtOAC MM053 4.8 ± 6.4 2.2 ± 3.1 21.5 ± 1.6 12.8 ± 8.3 
MeOH MM053 3.7 ± 5.2 2.7 ± 3.7 13.7 ± 12.1 3.3 ± 4.6 
Cordyceps ophioglossoides (Ehrh.) Link 
PE MM054 53.8 ± 8.8 16.5 ± 16.6 28.0 ± 1.8 4.7 ± 3.9 
EtOAC MM054 39.9 ± 13.1 12.3 ± 10.6 99.9 ± 0.1 75.0 ± 6.9 
MeOH MM054 22.7 ± 6.4 7.5 ± 5.2 6.9 ± 9.7 1.2 ± 1.7 
Elaphomyces granulatus Fr. 
PE MM055 100.0 ± 0.0 31.7 ± 19.2 65.2 ± 1.0 7.7 ± 6.3 
EtOAC MM055 100.0 ± 0.0 100.0 ± 0.0 100 ± 0.0 56.4 ± 5.1 
MeOH MM055 99.7 ± 0.5 100.0 ± 0.0 98.6 ± 2.1 38.7 ± 5.5 
Tricholoma sulphureum (Bull.) P. Kumm. 
PE MM056 11.8 ± 11.5 3.3 ± 2.7 6.8 ± 5.4 3.4 ± 4.8 
EtOAC MM056 7.6 ± 10.7 0.0 ± 0.0 13.3 ± 18.8 0.0 ± 0.0 
MeOH MM056 11.0 ± 15.6 7.3 ± 3.0 9.5 ± 0.3 3.7 ± 5.2 
Cortinarius venetus var monanus M.M. 
Moser 
PE MM057 12.9 ± 17.7 5.0 ± 2.1 22.0 ± 9.7 5.0 ± 7.0 
EtOAC MM057 8.8 ± 12.4 2.7 ± 2.8 27.8 ± 7.0 11.6 ± 5.0 
MeOH MM057 9.9 ± 8.5 5.9 ± 4.2 18.3 ± 1.6 5.6 ± 3.2 
Cortinarius elegantior (Fr.) Fr. 
PE MM058 5.9 ± 2.4 7.3 ± 6.7 9.7 ± 13.7 10.9 ± 15.4 
EtOAC MM058 12.5 ± 3.7 10.9 ± 10.7 11.0 ± 13.0 14.0 ± 19.0 
MeOH MM058 19.3 ± 10.0 11.9 ± 9.4 13.7 ± 19.3 6.8 ± 9.6 
Lactarius badiosanguineus Kühner et 
Romagn. 
PE MM059 14.1 ± 8.5 12.2 ± 5.2 15.1 ± 16.7 9.3 ± 13.2 
EtOAC MM059 11.2 ± 5.2 7.8 ± 0.1 26.8 ± 4.4 10.9 ± 15.4 
MeOH MM059 12.1 ± 0.3 17.3 ± 12.0 11.1 ± 14.4 17.5 ± 15.8 
Lactarius scrobiculatus (Scop.) Fr. 
PE MM060 24.1 ± 21.9 20.2 ± 18.3 18.4 ± 12.3 6.8 ± 9.5 
EtOAC MM060 17.8 ± 1.3 16.5 ± 8.9 23.0 ± 13.9 7.9 ± 11.2 
MeOH MM060 2.9 ± 4.0 2.3 ± 3.2 7.0 ± 9.9 5.4 ± 7.6 
Lactarius picinus Fr. 
PE MM061 4.8 ± 3.3 0.0 ± 0.0 8.2 ± 2.2 10.4 ± 14.7 
EtOAC MM061 4.8 ± 2.4 10.1 ± 12.0 11.0 ± 15.6  9.1 ± 12.9 
MeOH MM061 4.8 ± 3.8 1.8 ± 2.5 9.5 ± 13.4 7.6 ± 10.8 
Hygrocybe persistens (Britzelm.) Sing. 
var. langei (Kühner) Bon 
PE MM062 1.3 ± 1.8 0.0 ± 0.0 12.1 ± 17.0 9.3 ± 13.1 
EtOAC MM062 6.3 ± 4.7 0.1 ± 0.1 8.0 ± 11.2 5.7 ± 8.1 
MeOH MM062 0.0 ± 0.0 0.0 ± 0.0 14.1 ± 19.9 6.4 ± 6.0 
Tricholoma pseudonictitans Bon 
PE MM063 2.0 ± 2.8 1.8 ± 2.5 20.3 ± 19.8 8.9 ± 12.6 
EtOAC MM063 9.5 ± 4.9  0.8 ± 1.1 19.3 ± 27.2 7.7 ± 10.8 
MeOH MM063 15.1 ± 14.4 1.9 ± 2.5 8.9 ± 3.7 4.0 ± 5.7 
Meripilus giganteus (Pers.) P. Karst. PE MM04 9.9 ± 8.8 7.2 ± 3.8 24.2 ± 5.9 10.9 ± 15.3 
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Meripilus giganteus (Pers.) P. Karst. 
EtOAC MM064 3.0 ± 4.2 0.0 ± 0.0 8.5 ± 11.3 3.5 ± 5.0 
MeOH MM064 2.2 ± 3.1 0.0 ± 0.0 26.4 ± 18.7 22.6 ± 31.9 
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CHAPTER 3 
The first natural product with in vivo activity against T. b. 
rhodesiense 
 
Third publication: 
From the initial HTS campaign of more than 2000 extracts against T. b. rhodesiense was one 
of the most promising extract a DCM of the cornflower Centaurea salmantica (Asteraceae) 
with a growth inhibition of 61% tested at 4.81 μg/mL. Subsequent HPLC-based activity 
profiling led to the identification of cynaropicrin, a STL of the guajanolide type. Due to its high 
in vitro activity with an IC50 of 0.3 μM (SI 7.8) against T. b. rhodesiense the compound was 
tested i.p. at 10 mg/kg/b.i.d. using the acute sleeping sickness mouse model. A 92% 
reduction of parasitemia compared to untreated controls on day seven postinfection was 
determined. This is the first report of a NP with potent in vivo activity against T. b. 
rhodesiense [1].  
 
Upscaled extraction of plant material, isolation of cynaropicrin, interpretation of analytical 
data (HPLC-ESI-MS, HR-MS, NMR), removal of cynaropicrin’s side chain, IC50 
determinations against P. falciparum, T. b. rhodesiense, melarsoprol-, and pentamidine 
resistant T. b. rhodesiense strains, and cytotoxicity test, writing of the manuscript, and 
preparation of the figures and tables were my contribution to this publication. 
Stefanie Zimmermann 
 
 
 
 
 
[1] Zimmermann S, Kaiser M, Brun R, Hamburger M, Adams M (2012) Cynaropicrin: the first plant natural product 
with in vivo activity against Trypanosoma brucei. Planta Med 78: 553-556. 
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CHAPTER 4 
Structure-activity relationship study of sesquiterpene 
lactones and their semi-synthetic amino derivatives as 
potential antitrypanosomal products 
 
Fourth publication:  
 
Since cynaropicrin was not able to cure the acute sleeping sickness mouse model, a SAR 
study was set up, which included 18 natural STLs and 16 semi-synthetic STL amines. This 
small library was tested in vitro against T. b. rhodesiense and mammalian cancer cells for a 
better understanding of STLs structural features, which contribute to their activities. The 
conclusion is that the α-methylene-γ-lactone is necessary for both antitrypanosomal and 
cytotoxicity effects. 
 
In an attempt to improve CYN’s bioavailability, the exocyclic double bond in the lactone ring 
was masked to obtain a water soluble dimethylamino derivative. Both compounds (original 
and its prodrug) were orally administered in the acute sleeping sickness mouse model at 50 
mg/kg/d for four consecutive days. The in vivo toxic effects of the prodrug after oral 
application was less compared to the origin, but the mean survival time was the same as for 
the controls [1]. 
 
Determination of compounds IC50s against T. b. rhodesiense including their cytotoxicity 
assessments, organization of vernodalin from Prof. Ohigashi, writing of the manuscript, and 
preparation of the figure and the tables were my contribution to this publication. 
Stefanie Zimmermann 
 
 
 
 
 
[1] Zimmermann S, Fouche G, De Mieri M, Yoshimoto Y, Usuki T, Nthambeleni, van der Westhuyzen C, Kaiser M, 
Hamburger M, Adams M (2013) Structure-Antitrypanosomal activity-relationship study of  sesquiterpene lactones 
and their semisynthetic amino derivatives as potential antitrypanosomal products. J Med Chem, prepared for 
submission
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ABSTRACT 
Sesquiterpene lactones (STLs) are natural products, which have potent antitrypanosomal 
activity in vitro and, in the case of cynaropicrin, also reduce parasitemia in the murine model 
of trypanosomiasis. To explore structure-antitrypanosomal activity-relationships a set of 34 
natural and semi-synthetic STLs and amino-STLs was tested in vitro against T. b. rhodesiense 
(which causes East African sleeping sickness) and mammalian cancer cell (rat bone myoblast 
L6 cells). The conclusions are that the α-methylene-γ-lactone is necessary for both 
antitrypanosomal effects and cytotoxicity. Antitrypanosomal selectivity is facilitated by 2-
(hydroxymethyl)acrylate or 3,4-dihydroxy-2-methylenebutylate side chains, and by the 
presence of cyclopentenone rings. Semi-synthetic STL amines with improved activity over 
the native STLs were those with morpholino and dimethylamino groups. The dimethylamino 
analogue of cynaropicrin was prepared and tested orally in the T. b. rhodesiense acute mouse 
model, where it showed reduced toxicity over cynaropicrin, but also reduced 
antitrypanosomal effects. 
 
INTRODUCTION 
Sleeping sickness or Human African Trypanosomiasis (HAT) is a deadly protozoal disease, caused by 
Trypanosoma brucei species, and spread by tsetse flies (Glossina spp.). The two human pathogenic 
subspecies T. b. rhodesiense (95% of cases) and T. b. gambiense (5%) differ by geographic 
distributions, clinical pictures, and drugs used for their treatment.1 Currently there are about 30 000 
annual HAT cases, and as many as 30 million live in HAT endemic areas.2 Despite some recent 
successes like nifortimox-eflornithine combination therapy (NECT),3 HAT drugs are still insufficient 
by modern standards, and need to be replaced by drugs that are safer and easier to administer.4  
Natural products from plants have been instrumental in developing drugs to treat protozoal diseases 
like malaria (quinine, artemisinin),5,6 but currently no natural product based antitrypanosomal drugs is 
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in use or in late stage development. We recently reported the in vivo activity7 and mode of action8 of 
cynaropicrin (1) - a sesquiterpene lactone (STL). This was the first reported plant compound with in 
vivo anti-T. brucei effects, but more than 883 plant derived compounds have shown antiprotozoal 
(antitrypanosomal, antiplasmodial, and antileishmanial) effects in vitro, of which 87 were STLs.5,6 
STLs are a chemotaxonomic feature of the largest plant family, the Asteraceae,9 and to date more than 
5000 of them are known.5,10 STLs are a promising compound class for antitrypanosomal drug 
discovery,11-13 yet a better understanding of the structural features, which contribute to activity, is 
expedient.14,15 This study explores structure  activity relationships in a set of 18 natural STLs and 16 
semi-synthetic STL – amines against T. b. rhodesiense and mammalian cancer cell (L6 cells) in vitro. 
The antitrypanosomal effects of eight of the compounds including 1, 2, 5-8, 10, and 13 have been 
reported before 7,11,12, but were included for comparison. Additionally, based on the in vivo 
antitrypanosomal effects of 1 after intraperitoneal application,7,8 1 and the dimethylamino derivative 
19 were tested in vivo in the acute mouse model with oral application. The rationale behind derivative 
19 was that masking the α,β-unsaturated enone in the lactone ring would possibly create a prodrug 
with increased water solubility, improved pharmacokinetic properties, and reduced unspecific binding 
to biological thiols via Michael reaction of the α-methylene-γ-lactone. Through subsequent 
bioactivation it would be converted to the parent compound 1 and hence, display its biological activity 
on the target. A similar approach had been previously successfully applied to several STLs with 
anticancer activity like helenalin, costunolide, and parthenolide.16 
 
RESULTS and DISCUSSION 
In vitro activity of compounds 1-34 against T. b. rhodesiense (STIB 900 strain), cytotoxicity against 
mammalian cells (rat myoblast L6 cells), as well as selectivity indices (SI; IC50 L6 / IC50 T. b. 
rhodesiense cells) are shown in Table 1.  
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Chart 1. Structures of sesquiterpene lactones (STLs) 1-18 and semi-synthetic STL amino derivatives 
19-34. 
 
1 and onopordopicrin (2), which both had 2-(hydroxymethyl)acrylate side chains, showed IC50s of 0.3 
and 0.4 µM and SIs of 7.8 and 8.2, respectively. Prolongation of the 2s side chain to a 3,4-dihydroxy-
2-methylenebutylate as in cnicin (3) did not reduce activity (0.4 µM) or selectivity (SI: 10). 
Compound 5, which lacked the 2-(hydroxymethyl)acrylate side chain of 1, had a 16 fold lower 
antitrypanosomal activity (4.9 µM) and a nine fold lower cytotoxicity (19 µM) as compared to 1. The 
antitrypanosomal effects (IC50 4.4 µM) of dehydrocostuslactone (6), which lacks the two hydroxyl 
groups seen in 5, were similar to 5 but with reduced selectivity (SI 1.9). Costunolide (7) was slightly 
less active (IC50 1.3 µM) than its epoxy derivative parthenolide (8) (IC50 0.8 µM). Zaluzanin D (9) a 7-
acetoxy analogue of 6, had half the antitrypanosomal activity (11 μM) and reduced selectivity (SI 1.4) 
when compared to 6. Compound 10, which had a cyclopentenone ring, exhibited considerably higher 
activity (IC50 0.6 μM) against T. b. rhodesiense than 9 and 6. Compounds 12 and 13 (eupatoriopicrin) 
are 4-hydroxy-3-(hydroxymethyl)but-2-enate (12) and (E)-3-hydroxy-2-(hydroxymethyl)acrylate (13) 
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derivatives of 7. Their IC50s of 0.9 (12) and 1.2 µM (13) were similar to that of the parent compound 7 
(IC50 1.3 µM; SI 5.9), but their selectivity indices were lower (SIs of 2.5 (12) and 1.3 (13), 
respectively). Compound 14, a 2-methylbut-2-enate STL, was also less active and selective than the 2-
(hydroxymethyl)acrylate STLs 1, 2, and 3. Compounds 15-18, which lack of an exocyclic methylene 
group in the lactone ring, showed reduced antitrypanosomal activities (IC50s > 12 μM) and a total loss 
of their cytotoxicities.  
The antitrypanosomal activity of the semi-synthetic dimethylamino derivative 19 (IC50 0.5 µM) was 
moderately higher than that of the parent compound 1 (0.3 µM), whereas cytotoxicity was slightly 
decreased (SI 10.8 versus 7.8). Likewise derivative 20 was compared to its parent compound 5. It 
showed slightly higher potency against T. b. rhodesiense (IC50 3.6 µM for 20, and 4.9 µM for 5), but 
also higher cytotoxicity (SI 2.5 and 3.9, respectively). Compound 21 (IC50 4.2 µM), a diethylamide 
derivative of 15, was markedly more active than 15 (IC50 55 µM). The STL derivatives 22-25 had 
morpholino groups. The adduct 22 (IC50 0.7 µM) was as potent as parent compound 10 (IC50 0.7 µM), 
with slightly increased selectivity (SIs of 10.3 and 7.6, respectively). Compounds 23 and 24 showed 
little cytotoxicity (IC50s 65.6 µM and 31.3 µM, respectively), but 24 had much higher 
antitrypanosomal activity (IC50 2.4 µM) than 23 (IC50 11.8 μM). Compound 25 had a similar (IC50 2.6 
µM) activity against T. b. rhodesiense as 24.  
The STL 4-(2-aminoethyl)phenols 26-30 showed low cytotoxicities (IC50s 22.1 µM to > 236 µM), and 
29 had the highest antitrypanosomal activity (IC50 6.6 µM). The STL 1-(2-chlorophenyl)piperazine 31 
and the 2-(4-chlorophenyl)ethanamines 32-34 all showed low antitrypanosomal activity (IC50s >5 µM) 
and cytotoxicity (IC50s >20 µM). 
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Table 1. In vitro activity of compounds against STIB 900 strain and L6 cells 
 
Compound T. brucei STIB 900 IC50 (μM)
a L6 cells IC50(μM)
a 
 
SIb 
 
1 0.3 ± 0.001 2.2 ± 0.3 7.8 
2 0.4 ± 0.01 3.1 ± 1.1 8.2 
3 0.4 ± 0.1 4.2 ± 0.9 10 
4 0.2 ± 0.01 0.6 ± 0.02 3 
5 4.9 ± 0.34 19.2 ± 3.2 3.9 
6 4.4 ± 1.2 8.3 ± 1.9 1.9 
7 1.3 ± 0.4 7.7 ± 1.3 5.9 
8 0.8 ± 0.5 5.2 ± 0.9 6.5 
9 10.8c 15.6 1.4 
10 0.6 ± 0.2 4.3 ± 0.5 7.6 
11 5.8 ± 0.7 6.9 ±1.8 1.2 
12 0.9 ± 0.2 2.2 ± 0.1 2.5 
13 1.2 ± 0.2 1.6 ± 0.1 1.3 
14 3.1 ± 0.3 10.5 ± 0.1 3.4 
15 54.7 ± 8.0 353.2 ± 4.0 6.4 
16 45.7 ± 5.0 > 292.2  > 6.4 
17 41.5 ± 0.8 > 365.9 > 8.8 
18 12.9 ± 2.4 34.0 ± 1.5 2.6 
19 0.5 ± 0.003 5.2 ± 1.3 10.4 
20 3.6 ± 1.0 8.6 ± 1.3 2.5 
21 4.2 ± 0.8 9.4 ± 2.2 2.2 
22 0.7 ± 0.1 7.4 ± 0.8 10.3 
23 11.8 ± 2.7 65.6 ± 9.7 5.6 
24 2.4 ± 0.7 31.3 ± 1.4 13.3 
25 2.6 ± 0.5 9.9 ± 1.6 3.8 
26 6.7 ± 1.3 > 236.2 > 35.0 
27 13.0 ± 1.4 45.6 ± 3.2 4 
28 13.4 ± 1.1 87.9 ± 2.2 6.5 
29 6.6 ± 0.7 22.1 ± 4.0 3.3 
30 9.9 ± 1.6 31.8 ± 1.3 3.2 
31 7.0 ± 2.2 21.8 ± 2.7 3.1 
32 10.6 ± 1.5 34.8 ± 1.2 3.4 
33 10.2 ± 3.2 27.6 ± 6.7 2.7 
34 5.4 ± 1.1 22.5 ± 1.6 4.2 
Melarsoprold 0.01 ± 0.01       
Podophyllotoxine  0.02 ± 0.01  
a Average of three independent assays. b Selectivity Index (SI): IC50 against L6 cells divided by IC50 
against STIB 900 strain. c tested once. d positive control for STIB 900 assay. e positive control for 
cytotoxicity assay. 
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We recently reported in vivo antitrypanosomal effects of 1.7,8 Upon intraperitoneal administration, the 
parasitemia was decreased over several days, but the compound was not able to cure the mice when 
they were treated with 10 mg/kg/b.i.d. for four consecutive days. In an attempt to improve the 
bioavailability, the exocyclic double bond in the lactone ring was masked to obtain water soluble 
dimethylamino derivative 19. Compounds 1 and 19 were orally administered in the acute sleeping 
sickness mouse model. Four mice, each treated with 50 mg/kg body weight/day of 1, showed reduced 
parasitemia on day 7 after infection. However, the animals were euthanized on day 10 postinfection 
due to obvious signs of cytotoxicity of the compound. Mice treated with compound 19 exhibited less 
signs of toxicity. However, the compound showed no in vivo efficacy, since the mean survival time 
was the same as for the control (Table 2).  
 
Table 2. Activity of compound 1 and 19 in the STIB 900 mouse model of trypanosomiasis. 
Compound RAa dose (mg/kg) survival (days)b 
1 po 4 x 50 9.5 
19 
po 4 x 50 10 
po 4 x 25 8.5 
a RA, route of administration: oral (po). bAverage days of survival of all mice; untreated controls 
euthanized at day 10 postinfection. 
 
This structure activity relationship (SAR)-study showed the STL 2-(hydroxymethyl)acrylates 1, 2, and 
4 alongside the STL 3,4-dihydroxy-2-methylenebutylate 3 are the most active and selective STLs 
against T. b. rhodesiense. These compounds have two active α,β-unsaturated enone moieties in 
common of which one methylene group is at the lacton ring and the other exocyclic double bond is at 
the side chain. Compound 10 has no side chain with enone function but does possess a cyclopentenone 
group, which can serve as the additional reactive enone. In fact a third reactive α,β-unsaturated group 
found in vernodalin (4) is expressed in slightly better potency, but revealed higher toxicity than 1. 
These results are supported by decreased antitrypanosomal and cytotoxicity IC50s of corresponding 
STLs lacking side chains (5, 6),  not having reactive α,β-enone functions in their side chains (12, 13, 
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and 14), and  loss of the reactive terminal CH2 in both the lactone ring and the side. The results are in 
accordance with findings by others.16,17 Schmidt et al. (2009) showed in a SAR study with 40 STLs 
against the same structural features determined both antiprotozoal and cytotoxic activity α,β-
unsaturated structural elements.14 Many bioactivities in STLs have been attributed to a Michael 
addition of the methylene-γ-lactone motif to biological thiols.18 Recent findings on the molecular 
interactions of the two α,β-unsaturated nucleophilic enone groups at C13 and C3´ in 1 with 
trypanothione and glutathione in trypanosomes via a Michael addition show the long presumed STLs 
mode of action, alongside inhibition of ornithine decarboxylase.8 The same mode of action can be 
expected for 2, 3, and 4. Regarding the 14 semisynthetic tested STL amines it was observed that the 
addition of morpholine goup and dimethylamine groups maintained or even enhanced the activity and 
selectivity of their amino STL derivatives, whereas, 4-(2-aminoethyl)phenol groups, 2-(4-
chlorophenyl)ethanaminate groups or 1-(2-chlorophenyl)piperazine groups were not compared to their 
parent compounds.  
The in vivo toxic effects of 19 in the T. brucei rhodesiense acute mouse model after oral application 
were reduced compared to 1, but the antitrypanosomal effects were too. Further antitrypanosomal in 
vivo studies with other orally applied STL amino derivatives, are needed to demonstrate if the use of 
amino STLs as prodrugs is a reasonable approach to improving STLs suitability as antitrypanosomal 
drugs.  
EXPERIMENTAL SECTION 
Sample Preparation for Biological Testing. 
Compounds were dissolved in DMSO (10 mg/mL) and stored at -20 °C until testing. Fresh dilutions in 
medium were prepared for each biotest. Final test concentrations did not exceed a 1%. DMSO and 
assays were done at least three times independently. The purity of all compounds was > 95% if not 
stated otherwise.  
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Trypanosoma brucei rhodesiense (STIB 900 Strain) Bioassay. 
Evaluation of in vitro antiprotozoal activity against T. b. rhodesiense was done using the Alamar Blue 
assay to determine IC50s as previously described.19 Serial threefold dilution were prepared in 96-well 
micro titer plates and 4000 T. b. rhodesiense STIB 900 bloodstream forms in 50 μL were added to 
each well except for the negative controls. Melarsoprol (Arsobal®, purity > 95%, Sanofi-Aventis, 
Meyrin, Switzerland) was used as reference drugs. After 70 h of incubation 10 μL of Alamar blue 
marker (12.5 mg resazurin (Sigma-Aldrich, Buchs, Switzerland) dissolved in 100 mL of distilled 
water) was added, and color change was developed for 2 to 6 h. A Spectramax Gemini XS micro plate 
fluorescence reader (Molecular Devices Cooperation, Sunnyvale, CA) with an excitation wavelength 
of 536 nm and an emission wavelength of 588 nm was used to read the plates. The IC50 values were 
calculated from the sigmoidal growth inhibition curves using Softmax Pro software (Molecular 
Devices).  
Rat Myoblast Cell L6-Cytotoxicity Assay. 
The cytotoxicity assay was performed using the Alamar Blue assay described above with rat skeletal 
myoblasts (L6-cells) seeded in 100 μL RPMI 1640 in 96-well micro titer plates. After 24 h the 
medium was removed and replaced by 100 μL of fresh RPMI 1640 with serial threefold drug dilution. 
Podophyllotoxin (purity > 95%, Sigma-Aldrich) was used as a reference drug. After 70 h of incubation 
under a humidified 5% CO2 atmosphere, 10 μL of the Alamar blue marker (see above) was added to 
all wells. The plates were incubated for an additional 2 h. A Spectramax Gemini XS micro plate 
fluorescence reader (Molecular Devices) was used to read the plates using an excitation wavelength of 
536 nm and an emission wavelength of 588 nm. The IC50s were calculated from the sigmoidal growth 
inhibition curves using Softmax Pro software (Molecular Devices). 
Acute Mouse Sleeping Sickness Model. 
This model mimics the first stage of the human African trypanosmiasis. Adult female NMRI mice 
were purchased from Janvier (St. Berthevin, France). They weighed between 20 and 25 g at the 
beginning of the study and were kept under standard conditions in macrolon type III cages with food 
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pellets and water ad libitum at 22 °C and 60-70% humidity. All protocols and procedures used in this 
study were reviewed and approved by the local veterinary authorities of the Canton Basel-Stadt, 
Switzerland (authorization N° 739; 11.12.2009). The samples were first dissolved in 100% DMSO 
followed by addition of distilled H2O to a final DMSO concentration of 10%. For the establishment of 
the in vivo antitrypanosomal activity, the mice were infected intraperitoneally with 1 x 104 STIB900 
bloodstream forms. Experimental groups of four mice were treated orally once a day on four 
consecutive days from day 3 to day 6 post infection. A control group of four mice was infected, but 
remained untreated. The determination of the parasitemia was done on day 7 post infection. Six μL of 
tail blood were diluted in 24 μL sodium citrate (3.2%), whereby the first μL was discarded to obtain 
circulating blood. Five μL of this mixture were transferred to a glass slide and covered with an 18 x 18 
mm cover slide. The sample was examined under a light microscope (200-fold magnification) and 
parasites were counted in 3 of the 16 squares of the grid. 
Test compounds 
Cynaropicrin (1) was isolated from artichoke leaves as previously reported.7 Compound 5 was 
prepared by mild alkaline hydrolysis of 1 as described by Zimmermann et al.7 Zaluzanin D (9) and 
dehydrocostuslactone (6), were isolated from Saussurea costus as referenced.11 Compounds 1020 and 
1621 were synthesized according to literature methods. Vernodalin (4) was provided from Prof. Hajime 
Ohigashi, Kyoto University, Japan. Psilostachyin A (11) was kindly supplied by Dr. Wolfgang 
Schühly, University of Graz, Austria. Onopordopicrin (2) was isolated from Arctium nemorosum.12 
Nobilin (14) was kindly supplied by Prof. Imanidis from the University Applied Sciences and Arts 
Northwestern Switzerland. Compound 12 was from Prof. Merfort,University of Freiburg, Germany. 
Cnicin (3) was isolated from Cnidus benedictus L22. Eupatoriopicrin (13), costunolide (7), and 
parthenolide (8) were isolated from Saussurea costus.11 Santonin (17) was purchased from Fluka 
Chemie (Buchs, Switzerland, > 98% purity). Compounds 18, 21-32, and 34 were synthesized as 
detailed elsewhere.20, 23 
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General Experimental Information.  
NMR spectra were run on a 400 MHz Varian INOVA instrument. Samples were referenced against 
chloroform at 77.00 ppm for 13C and against tetramethylsilane at 0.00 ppm for 1H. High resolution 
mass spectra were recorded on a Waters SYNAPT G1 HDMS mass spectrometer operated in 
electrospray mode. Leucine enkephalin (50 pg/ml) was used as reference calibrant to obtain typical 
mass accuracies between 1 and 3 mDa. Melting points were determined using a Mettler FP62 capillary 
melting point apparatus and are uncorrected. All reagents were of reagent grade purchased from 
Sigma-Aldrich (Schnelldorf, Germany) and were used without any further purification. Solvents used 
for chromatography or extractions were distilled prior to use. Thin-layer chromatography was carried 
out using pre-coated aluminum-backed plates (Merck Silica Gel 60 F254). Column chromatography 
was performed on Fluka silica gel 60 (70–230 mesh). Dry solvents were purified as described by 
Perrin and Armarego.24 All starting materials were obtained commercially and used without further 
purification. 
 ((3S,3aS,6R,9bS)-6,8-dihydroxy-3,6,9-trimethyl-3,3a,4,5,6,6a,7,8-octahydroazuleno[4,5-b]furan-
2(9bH)-one) (15). 
A solution of O-acetylisophotosantonin (1.475 g, 4.813 mmol) in MeOH (49 mL) at 0 ºC was treated 
with NaBH4 (0.293 g, 7.750 mmol) carefully. The reaction was left at 0 ºC for 3 h, then left to warm to 
room temperature overnight. The mixture was extracted from saturated aqueous NH4CL (50 mL) with 
EtOAc (3 x 50 mL), the extracts pooled and dried (MgSO4). The dried filtrate was concentrated to a 
tacky white foam, then dissolved in EtOH (16 mL). 5% aqueous KOH (150 mL) was added and the 
mixture stirred for 18 h at rt. The mixture was acidified to pH < 2 with 18% aqueous HCL, stirred for 
30 min, extracted with EtOAc (3 x 50 mL) and washed with saturated aqueous K2CO3. Concentration 
yielded a yellow solid, which was recrystallized (EtOAc/hexane) to a white amorphous powder (0.313 
g, 36%). NMR showed an approximately 2.2:1 mixture of secondary alcohols had been isolated. δH 
(400 MHz, CDCl3 + CD3OD) 4.73 (1H, d, J 11.0), 4.64 (0.4H, d, J 11.0), 4.54 (0.4H, d, J 7.1), 4.49 
(1H, t, J 6.8), 2.90 (1H, br td, J 1.9, 7.5), 2.45 (1H, dt, J 8.0 and 13.8), 2.34 – 2.12 (2H, m), 2.03 – 
1.91 (4H, m), 1.91 – 1.79 (5H, m), 1.65 (1H, dd, J 2.3 and 16.0), 1.61 (1H, td, J 6.7 and 13.7), 1.46 – 
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1.30 (1.5H, m), 1.22 (1H, d, J 6.9), 1.22 (3H, d, J 6.9), 1.03 (3H, s), 0.91 (1H, s); δC (101MHz, CDCl3 
+ CD3OD) 178.82, 178.71, 143.96, 143.79, 133.32, 131.28, 82.04, 81.71, 79.59, 76.97, 74.40, 74.23, 
55.57, 54.31, 48.96, 48.92, 44.87, 44.27, 41.51, 41.34, 34.81, 34.36, 25.41, 25.26, 20.88, 20.56, 13.23, 
12.23, 12.20; HRMS (ESI) calculated C15H21O3 249.1491, found 249.1423 (MH+ - H2O); and 
calculated C15H21O4 265.1440, found 265.1392 (MH+ - H2). 
 
 (3R,3aR,4S,6aR,8S,9aR,9bR)-3-((dimethylamino)methyl)-8-hydroxy-6,9-dimethylene-2-
oxododecahydroazuleno[4,5-b]furan-4-yl 2-(hydroxymethyl)acrylate (19). 
To a cold solution of 1 (0.50 g; 1.44 mmol) in absolute EtOH (15 mL), dimethylamine, (0.72 mL, 2.0 
M solution in MeOH) was added under argon atmosphere. The solution was stirred at 5 ºC for 5 h, 
then concentrated under reduced pressure and recrystallized from acetone/Et2O. The amino adduct 
(0.222 g; 0.566 mmol) was then dissolved in MeOH (5 mL) and a solution of  HCL (0.45 mL; 1.25 N 
solution in MeOH) was added dropwise. After evaporation of the solvent the compound 19 was 
recovered as a yellow solid (0.242 g; 40%). 1H NMR (500 MHz, CD3OD): δ 6.28 (s, 1H), 5.97 (s, 1H), 
5.31 (m, 2H), 5.15 (m, 2H), 5.00 (s, 1H), 4.50 (dt, J  8.0, 2.0 Hz, 1H), 4.44 (m, 1H), 4.30 (s, 2H), 3.62 
(m, 1H), 3.50-3.42 (m, 2H), 3.03-2.91 (m, 8H), 2.83 (m, 1H), 2.72 (m, 1H), 2.33 (dd, J  13.4 and 7.0 
Hz, 1H), 2.26-2.16 (m, 1H), 1.77-1.68 (m, 1H); 13C NMR (125 MHz, CD3OD): δ 177.55, 166.72, 
154.17, 143.95, 141.84, 127.82, 117.58, 111.28, 81.77, 77.26, 73.82, 61.98, 58.34, 50.74, 49.85, 
44.98, 44.77, 42.02, 40.54, 39.51. HRMS (ESI) calculated for C21H29NO6  [M+H]+, 392.2067; found 
392.2062. 
 
 (3R,3aR,4S,6aR,8S,9aR,9bR)-3-((dimethylamino)methyl)-4,8-dihydroxy-6,9-
dimethylenedecahydroazuleno[4,5-b]furan-2(9bH)-one (20). 
To a cold solution of 5 (0.050 g; 0.191 mmol) in absolute EtOH (5 mL), dimethylamine, (0.1 mL, 2.0 
M solution in methanol) was added under argon atmosphere. The solution was stirred at 5 ºC for 5 h 
and then the mixture was concentrated under reduced pressure. The crude residue was then purified by 
column chromatography on silica gel (CH2Cl2/MeOH 9:1) to afford compound 20 as a yellow oil 
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(0.052 g; 88 %). 1H NMR (500 MHz, CD3OD): δ 5.32 (br s, 1H), 5.28 (br s, 1H), 5.05 (br s, 1H), 5.00 
(br s, 1H), 4.48 (tt, J  10.6, 7.3 and 2.6 Hz, 1H), 4.16 (dd-app. t , J  9.7 Hz, 1H), 3.67 (ddd, J  9.0, 7.3 
and 5.0 Hz, 1H), 3.02-2.80 (m, 4H), 2.73-2.64 (m, 2H), 2.40 (s, 6H), 2.26-2.14 (m, 3H), 1.70 (ddd, J  
12.8, 9.7 and 8.8 Hz, 1H); 13C NMR (125 MHz, CD3OD): δ 177.71, 154.33, 145.14, 116.01, 111.70, 
80.53, 74.00, 60.81, 58.34, 50.53, 46.44, 44.89, 44.82, 43.08, 39.49. HRMS (ESI) calculated for 
C17H25NO4  [M+H]+, 308.1856; found 308.1862. 
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CHAPTER 5 
Mode of action of cynaropicrin 
 
Fifth publication: 
Trypanosomatids have a unique trypanothione-based redox metabolism to deal with 
oxidative stress, which replaces the nearly ubiquitous GSH redox system. Because the 
trypanothione redox system exclusively occurs in trypanosomatids it represents several 
promising targets such as direct interference with GSH and T(SH)2, trypanothione reductase, 
trypanothione synthetase, and ornithine decarboxylase.  
This publication demonstrated that the uptake of CYN lead to a rapid and complete depletion 
of GSH and T(SH)2 within 5 min. in the trypanosomes. This action was based on the 
formation of CYN-thiol adducts by Michael-addition with CYN’s reactive exocyclic α,β-
unsaturated moieties and GSH and T(SH)2. Irreversible phenotypic changes of the 
trypanosomes to a stumpy-like form in cell deterioration and death were observed. 
Additionally, LC-MS/MS ornithine quantification studies indicated that CYN is a potent ODC 
inhibitor.  
This puplication proves the longstanding theory that STLs effect intracellular thiol levels in 
general and T(SH)2 in particular [1]. 
 
Preparation and structure elucidation of T(S-CYN)2 and GS-CYN, development of intra,- and 
extracellular extraction protocol, stability test for CYN-thiol peptide adducts, extraction control 
analysis, quantitative analysis of CYN, T(SH)2, GSH, GS-CYN, T(S-CYN)2, and ornithine  
from intact T. b. rhodesiense cells and from the extracellular milieu by UHPLC-MS/MS, 
investigation of protein-binding of CYN during the extraction of the extracellular milieu, writing 
of the manuscript, and preparation of all figures and tables.  
Stefanie Zimmermann 
 
 
[1] Zimmermann S, Oufir M, Leroux A, Krauth-Siegel R, Becker K, Kaiser M, Brun R, Hamburger M, Adams M 
(2013) Cynaropicrin targets the trypanothione redox system in Trypanosoma brucei. Int J Antimicrob Agents, 
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Abstract 
In mice cynaropicrin (CYN) potently inhibits the proliferation of Trypanosoma brucei - the 
causative agent of Human African Trypanosomiasis - by a so far unknown mechanism. We 
hypothesized that CYNs α,β-unsaturated methylene moieties act as Michael acceptors for 
glutathione (GSH) and trypanothione (T(SH)2), the main low molecular mass thiols essential 
for unique redox metabolism of these parasites. The analysis of this putative mechanism and 
the effects of CYN on enzymes of the T(SH)2 redox metabolism including trypanothione 
reductase, trypanothione synthetase, glutathione-S-transferase, and ornithine decarboxylase 
are shown. A two step extraction protocol with subsequent UPLC-MS/MS analysis was 
established to quantify intra-cellular CYN, T(SH)2, GSH, as well as GS-CYN and T(S-CYN)2 
adducts in intact T. b. rhodesiense cells. Within minutes of exposure to CYN, the cellular 
GSH and T(SH)2 pools were entirely depleted, and the parasites entered an apoptotic stage 
and died. CYN also showed inhibition of the ornithine decarboxylase similar to the positive 
control eflornithine. Significant interactions with the other enzymes involved in the T(SH)2 
redox metabolism were not observed. Alongside many other biological activities 
sesquiterpene lactones including CYN have shown antitrypanosomal effects, which have 
been postulated to be linked to formation of Michael adducts with cellular nucleophiles. Here 
the interaction of CYN with biological thiols in a cellular system in general, and with 
trypanosomal T(SH)2 redox metabolism in particular, thus offering a molecular explanation 
for the antitrypanosomal activity is demonstrated. At the same time, the study provides a 
novel extraction and analysis protocol for components of the trypanosomal thiol metabolism. 
 
Keywords: Sesquiterpene lactone, Trypanosoma brucei, trypanothione, drug target, HPLC-
MS/MS
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1. Introduction 
Human African Trypanosomiasis (HAT) is a deadly parasitic disease, which is caused 
by Trypanosoma brucei sub-species, and spread by the bite of the tsetse fly (Glossina spp.). 
As there is no vaccination chemotherapy remains the principal control of HAT. Severe side 
effects, treatment failures and complex administration schemes urgently demand for safer 
orally administerable drugs [1]. 
Several pathways in trypanosomes may provide suitable targets for new drugs 
including ergosterol- and purin biosynthesis, various kinases, farnesyl transferase, 
proteases, pyrimidine biosynthesis, compartmentalized glycolysis, and finally trypanothione-
based redox metabolism [2] (Fig. 6), with which a reducing intracellular milieu is maintained 
[3,4]. Because the trypanothione redox system is unique to trypanosomatids it represents 
several promising drug targets such as trypanothione synthetase (TryS), trypanothione 
reductase (TR), spermidine synthase (SpS), and ornithine decarboxylase (ODC), or by direct 
interaction with glutathione (GSH) and trypanothione (T(SH)2) (Fig. 6) [5]. 
We recently reported that cynaropicrin (CYN), a sesquiterpene lactone (STL) found in 
artichokes (Cynara scolymus L.) and some species of cornflowers (Centaurea spp.), inhibits 
the proliferation of T. b. rhodesiense in the acute mouse model [6]. CYN is the so far only 
plant compound demonstrated to have in vivo anti T. b. rhodesiense activity. Numerous other 
STLs have, however, shown antitrypanosomal effects in vitro [7]. Schmidt et al. supplied two 
excellent reviews of antiprotozoal in vitro effects of 883 plant derived natural products 
including 83 STLs [7,8]. The authors showed in a QSAR study of 40 STLs, that the 
antitrypanosomal activity was linked to the presence of the α-methylene-γ-lactone group 
[9,10]. Numerous biological activities by STLs have been attributed to the covalent binding of 
the reactive α-methylene-γ-lactone to sulfhydryl groups in biomolecules like L-cysteine and 
GSH via a nucleophilic Michael addition [11-13].  
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Considering trypanosomes depend on their trypanothione-based redox system as a 
sole means of detoxification [14], and CYN contains reactive exocyclic α,β-unsaturated keto 
moieties (Fig. 1) [6], it was assumed that CYN may interact with GSH and/or T(SH)2.  
Here efficient extraction protocols for CYN, the thiol peptides T(SH)2 and GSH, as 
well as GS-CYN and T(S-CYN)2 adducts from T. b. rhodesiense parasites were developed 
and validated, and the use of ultra high performance liquid chromatography separation 
methods combined with tandem mass spectrometry methods (UPLC-MS/MS) to quantify 
these in part per billion (ppb) concentrations are described. Furthermore, the direct effects of 
CYN on various enzymes involved in T(SH)2 redox metabolism, TryS, TR, and ODC were 
assessed.  
2. Material and methods 
2.1. Solvents and reagents 
CYN was isolated as previously described [6]. GSH and forskolin were obtained from 
LC laboratories (Woburn, USA); γ-Glu-Ala-Gly (EAG) was synthesized by GeneCust 
(Dudelange, Luxembourg); T(SH)2 was synthesized as previously described [15]; 
dithiothreitol (DTT) and bovine serum albumin (BSA) were from Sigma-Aldrich (Switzerland); 
H2O was obtained from an EASYpure II water purification system (Barnstead; Dubuque, IA, 
USA); acetonitrile, methanol, and formic acid (FA) were all UPLC-MS grade from BioSolve 
(Valkenswaard, Netherlands); N2 was produced with a generator (Schmidlin Labor + Service 
AG, Neuheim, Switzerland); argon was from Carbagas (Basel, Switzerland); sodium 
phosphate (Na2HPO4) was from Fluka Chemika; NaCl from Scharlau (Barcelona, Spain), 
glucose monohydrate from Biochemika, Applichem (Darmstadt, Germany); DFMO was a gift 
of Dr. Cyrus Bacchi, (Pace University, New York, USA); and DMSO-d6 was from Armar 
Chemicals (Döttingen, Switzerland). 
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2.2. Preparation and structure elucidation of T(S-CYN)2 and GS-CYN 
CYN (45 μM) was incubated with either T(SH)2 or GSH (both 450 μM) in H2O (+0.1 % 
FA) supplemented with 250 μM DTT, for 10 min at room temperature (rt). Ten µL of the 
reaction solution were analyzed by HPLC-MS using an Agilent series 1100 HPLC system 
(Agilent, Heilbronn, Germany), coupled to an Esquire 3000 Plus ion trap mass spectrometer 
(Bruker Daltonics, Bremen, Germany). Separation conditions: A SunFire RP-18 column (3.5 
μm, 3 x 150 mm, Waters GmbH, Eschborn, Germany) at rt was used. The mobile phase 
consisted of A: H2O + 0.1% FA, and B: acetonitrile + 0.1% FA. The pump program was 10%-
100% B in 20 min, and 100% B for 5 min; the flow rate was 0.5 mL/min The CYN-thiol 
peptide adducts eluted at retention time (tR) 2.1 min (T(S-CYN)2) and 
tR 2.4 min (GS-CYN), 
respectively. They were collected, dried under N2 (Thermolyne Dri-Bath, Ismatec SA, Zürich, 
Switzerland), and subjected to 1H NMR measurements in 70% H2O and 30% DMSO-d6 using 
a Bruker Avance IIITM 500 MHz spectrometer (Bruker, Fällanden, Switzerland) [16]. 
2.3. Quantitative analysis of CYN, T(SH)2, GSH, GS-CYN, and T(S-CYN)2, from 
intact T. b. rhodesiense cells by UHPLC-MS/MS 
Ultra high performance liquid chromatography (UHPLC-MS/MS): An Acquity UHPLC 
(Waters Corp., Milford, USA) coupled to an Acquity tandem quadrupole MS detector (TQD) 
was used with cooled autosampler set to 10 °C protected from light and a column heater set 
to 45 °C. Separation conditions: UHPLC HSS T3 column (1.8 μm, 100 mm x 2.1 mm, Waters 
Corp., Milford, USA), H2O (+0.1% FA) 100 - 0% in 4 min, 100% acetonitrile (+0.1% FA) for 1 
min; the flow rate was 0.5 mL/min. Data were acquired with MassLynx V4.1 software and 
processed for quantification with QuanLynx V4.1 (Waters Corp., Milford, USA) in positive 
ionization mode (ESI+), with argon as collision gas. MS/MS parameters were determined 
automatically by Waters IntelliStart software and optimized manually afterwards. The source 
temperature was 150 °C and desolvation temperatures were 300 – 400 °C. Table 1 
summarizes the MS/MS parameters [17]. 
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2.4. Quantitative analysis of ornithine from intact T. b. rhodesiense cells by UHPLC-
MS/MS 
UHPLC was performed on an Agilent 1290 Infinity (Agilent Technologies, Santa Clara, CA) 
series instrument equipped with a binary pump (G4220A), an autosampler (G4226A) 
regulated at 10°C (G1330B), a thermostatted column compartment (G1316A) at 80°C and a 
Flexcube (G4227A). Separation conditions: An Acquity UHPLC BEH amide column, 50 x 2.1 
mm, 1.7 µm (Waters Corp., Milford, MA, USA) was used, the flow rate was 0.5 mL/min, H2O 
(+0.1% FA) 95 - 5% in 2.5 min, 100% acetonitrile (+0.1% FA) for 0.5 min. Tandem mass 
spectrometry analysis was performed on an Agilent Technologies 6430 Triple Quadrupole 
MS/MS system (Agilent Technologies, Santa Clara, CA), with a MassHunter software 
B.05.00 workstation. ESI+ mode was used for ornithine with the following settings: capillary 
voltage 4000 V, source temperature 350°C, Electron-Multipler Voltage 500 V, drying gas 
(pure nitrogen) flow 13 L/min, and nebulization pressure of 60 psi (Table 1). 
2.5. Stock solutions of standards 
Stock solutions (SS, 1 mg/mL) of GSH and T(SH)2 were prepared in H2O (+0.1% FA) 
supplemented with a 20 fold excess of DTT. Ornithine SS (1 mg/mL) was solved in H2O 
(+0.1% FA). CYN was dissolved in DMSO, and T(S-CYN)2 and GS-CYN were prepared in 
H2O:DMSO mixtures (70:30, v/v) with further dilution in H2O (+0.1% FA) to contain < 1% 
DMSO in the bioassays. SSs were prepared freshly on a daily bases. 
2.6. Stability test for CYN-thiol peptide adducts 
The stabilities of the SSs of CYN, GSH and the GS-CYN-monoadduct were 
monitored directly before and after 72 h of storage at rt unprotected from light. Generally, 
good stabilities were observed for all compounds. At time point zero and after 72 h storage, 
the concentrations of CYN, GSH, GS-CYN-monoadduct differed by less than 5%, when 
analyzed by UPLC-MS/MS (data not shown).  
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2.7. Quantification of CYN, T(SH)2, GSH, GS-CYN, T(S-CYN)2, and ornithine in T. b. 
rhodesiense 
T. b. rhodesiense (STIB 900) bloodstream forms were grown in Minimum Essential 
Medium (MEM) with Earle’s salts supplemented with 0.2 mM 2-mercaptoethanol as 
described by Baltz et al. [18] with the following modifications: 1 mM sodium pyruvate, 0.5 mM 
hypoxanthine, and 15% heat-inactivated horse serum.  
2.7.1. Preparation of cell lysates for the analysis of cell contents 
Trypanosome cultures were grown to a density of 2.0 x 106 cells/mL in 50 mL flasks and 
CYN was added (resulting in 50 μM; final DMSO concentration < 1%). After incubation for 0, 
5, 10, 20, 30, and 40 min, the samples were transferred into 50 mL Falcon tubes (Eppendorf, 
Germany) and centrifuged for 5 min at 3500 rpm, rt (Rotina 420 R, Hettich Zentrifugen, Bäch, 
Switzerland). The cell pellets were washed twice with 1.0 mL sodium phosphate buffer, pH 
8.0 (60 mM Na2HPO4, 44 mM NaCl, 50 mM glucose monohydrate) and lysed by adding 0.5 
mL H2O (+0.1% FA). After centrifugation for 2 min at 13’200 rpm, rt (Eppendorf Centrifuge, 
5415, Switzerland) the lysates were transferred into 96 deep-well plates. Thiol peptides 
(GSH and T(SH)2), CYN, GS-CYN, T(S-CYN)2, and ornithine were then immediately 
quantified by UHPLC-MS/MS. This was done for at least three independent experiments. To 
calculate the intracellular concentration of analytes in trypanosomes, the concentration in the 
UHPLC-MS/MS samples was multiplied by the dilution factor of the pellets during lysis. The 
pellets volume was calculated as the cell density determined in the culture before 
centrifugation times the volume of a trypanosome (58 femtolitres) [14]. 
2.7.2. Analysis of the extracellular milieu 
 After centrifugation of the 50 mL STIB 900 culture in the Falcon tubes an aliquot of 
200 μL supernatant was extracted with 150 μL BSA solution (60 g/L) and 1.0 mL ice cold 
acetonitrile. The samples were shaken for 10 min at 1400 rpm, rt (thermomixer compact, 
Eppendorf, Switzerland) and centrifuged for 20 min at 1200 rpm, rt (centrifuge mini Spin plus, 
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Eppendorf, Switzerland). The supernatants were transferred to 96 deep-well plates 
(Eppendorf, Germany). GSH and T(SH)2, CYN, GS-CYN, and T(S-CYN)2 were immediately 
quantified by UHPLC-MS/MS. 
2.7.3. Extraction control 
Forskolin was used as internal standard (IS) for CYN. EAG, a synthetic GSH 
homologue, where the cysteine is replaced by alanine to prevent adduct formation with CYN, 
served as IS for GSH and T(SH)2 (Fig. 1). Either forskolin or EAG (SS 1 mg/ml) was added 
to the 0.5 mL extraction solutions. For further sample preparation see section 2.7.1. 
Additionally, forskolin was used as a control for the efficiency of the extraction of the 
supernatant (see 2.7.2). Both the cell extraction controls and the supernatant extraction 
controls were analyzed in three independent experiments. Recovery factors were calculated 
in percentage and included in the quantification of the thiol-adducts in vitro. MS/MS 
parameters for standards are shown in Table 1.  
2.7.4. Investigation of protein-binding of CYN during the extraction of the supernatant 
CYN was quantified in the supernatant using a modified protocol: 50 mL medium 
without parasites was exposed to 50 μM CYN. Sample preparation and UHPLC-MS/MS 
analysis were done three times independently as in 2.7.2., and percentages of recovery were 
included into the thiol-adduct quantification study. Quantification of 50 μM in 50 mL medium 
yielded 21.7 ± 0.2 μM free CYN, meaning the total loss during the supernatant extraction 
step was 56.6%. Albumin was not used in the cell extraction protocol, which is why this 
experiment was not done for that setup. 
2.8. Enzymatic assays 
2.8.1. T. cruzi trypanothione reductase (TcTR) 
Reversible inhibition of TcTR was studied as described by Jockers-Scherübl [19]. The 
assay contained in a total volume of 1 mL: 40 mM Hepes, 1 mM EDTA; pH 7.5, 100 μM 
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NADPH, and 200 μM CYN (4 mM stock solution in DMSO) or the respective amount of 
DMSO and 2 to 4 nM TcTR. The reaction was started by adding 96 μM TS2 and the 
absorption decrease at 340 nm was followed at 25 °C. For detecting putative irreversible 
inhibition, 1 µM TR was incubated at 25 °C with 100 or 200 µM of CYN in the presence and 
absence of 625 µM NADPH. After 0.5, 5, 20, 25, 60, 120, 180, 183, 240 min, a 3 µL aliquot 
was removed and the remaining activity was measured in a standard assay.  
2.8.2. T. brucei trypanothione synthetase (TbTryS) 
TbTryS activity was measured at 25 °C by coupling the ATP hydrolysis to NADH 
consumption as previously described [20]. The reaction mixture contained in a total volume 
of 1 mL of 100 mM Hepes, pH 8.0, 0.5 mM EDTA, 10 mM MgCl2, 200 μM NADH, 1 mM 
phosphoenolpyruvate, 2 U pyruvate kinase, 2 U L-lactate dehydrogenase, about 350 nM 
TbTryS, 200 µM CYN (stock solution 4 mM in DMSO) or 50 µL DMSO, 2.5 mM ATP, and 0.1 
mM GSH. The reaction was started by adding 8 mM spermidine. To test for covalent 
inactivation, 6.9 µM TryS was preincubated with 200 µM CYN at 25 °C. After 0, 25, 60, 120, 
180, 240, and 300 min, a 50 µL aliquot was removed and the remaining activity measured in 
a standard assay. 
2.8.4. T. b. rhodesiense ornithine decarboxylase (ODC) in STIB900 cells 
 Ornithine levels were monitored from 2 x 106 T. b. rhodesiense (STIB900) cells (see 
2.7.1.) after 20 min of exposure to 50 µM CYN by UHPLC-MS/MS. In parallel, experiments 
with the positive control DFMO (50 µM) were done (see Table 1). 
3. Results 
The working hypothesis for this study was that CYN shows trypanocidal activity, 
because it binds to the thiol moieties of T(SH)2 and GSH, thus affecting the redox 
homeostasis of the parasites. To prove this it was first necessary to synthesize the reference 
compounds GS-CYN and T(S-CYN)2, and confirm their structures (see 2.2.). CYN was mixed 
with either T(SH)2 or GSH and the reaction solution was subjected to HPLC-MS. In the case 
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of T(SH)2, the chromatogram (in positive ESI mode) showed the educts plus one major peak 
(tR: 2.45 min) with a mass of 1070.4 m/z [M+H]+, and its corresponding double charged ion of 
535.8 m/z [M/2+H]+. This indicated that CYN had formed an adduct with T(SH)2. The LC-MS 
analysis of the GS-CYN reaction solution (in positive ESI mode) showed two main peaks in 
addition to the educts. The MS spectrum of the first peak (tR: 5.20 min) showed a mass of 
654.1 m/z [M+H]+, indicating a GS-CYN monoadduct. The second peak (tR: 4.10 min), whith 
an 80 times lower intensity, showed a mass of 961.2 m/z [M+H]+ and a double charged ion 
481.2 m/z [M/2+H]+, indicating a bisadduct of two GSHs with one CYN. The GS-CYN and 
T(S-CYN)2 adducts were isolated by HPLC, dried under N2, and their structures elucidated by 
1H NMR (Fig. 2 and 3). The spectrum of T(S-CYN)2, when compared to those of CYN and 
T(SH)2, showed that the proton signals at exocyclic double bonds at position 13 (5.8 and 6.2 
ppm, both d), and 3’ (5.5 and 6.2 ppm; both d) had disappeared (Fig. 1). This confirmed that 
the isolated product was a bisadduct in which CYN had reacted with both thiol groups of 
T(SH)2 via a Michael addition on the positions C13 and C3’ (Fig. 2). Because T(SH)2 consists 
of two GSH units with a spermidine - an unsymmetrical molecule - as linker, there are two 
possible isomers of the T(S-CYN)2 bisadduct linked at C13 and C3’, which could not be 
differentiated here. The 1H spectrum of the GS-CYN adduct lacks the proton signals of the 
exocyclic double bond at the lactone ring, indicating that GSH had reacted with this exocyclic 
methylene group (Fig. 3). 
The next step was to verify that these CYN-thiol adducts are actually formed in the 
living parasites. The parasites were treated with 50 µM CYN, harvested, lysed and analyzed 
at different time points by UHPLC-MS/MS. After 5 min, an extracellular concentration of 35 
µM CYN, and intracellular concentrations of 23 ± 5 μM CYN, 42 ± 17 μM GS-CYN-
monoadduct, and 49 ± 18 μM T(S-CYN)2-bisadduct were measured. A complete depletion of 
the parasites intracellular reduced free thiol pool, which had been 104 ± 28 μM GSH and 729 
± 103 μM T(SH)2 at time point zero (Fig. 4) was observed. Over 40 min of exposure to CYN 
the concentration of the CYN-thiol adducts gradually decreased to concentrations below the 
LLOQ (Table 1). Concentrations of T(SH)2, GSH, GS-CYN, and T(S-CYN)2 measured in the 
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extracellular milieu were all below LLOD. The depletion of intracellular GSH and T(SH)2 was 
irreversible, which was shown by washing the cells after exposure to 50 μM CYN for 5, 10, 
20, 30, and 40 min and replacing the supernatant with fresh medium, where it was observed, 
that the trypanosomes were not able to recover, and inevitably died (data not shown). 
In parallel to the UHPLC-MS/MS analysis, the CYN treated trypanosomes were 
observed under a light microscope (Leitz, Wetzlar, Germany). After 0, 5, 10, 20, 30 and 40 
min of incubation, the parasites were stained with Giemsa (Merck, Darmstadt, Switzerland), 
and phenotypes were evaluated. The trypanosomes, which at time point zero had shown the 
regular slender form, transformed within 5-10 minutes of exposure to CYN into an 
intermediate form, and finally into a stumpy-like form, and died. The stumpy-like form is 
indicative of an apoptosis-like behavior (Fig. 4) [21]. 
As shown above, there was no detectable free GSH and T(SH)2 left in the cells after 5 
min of incubation with 50 µM CYN. The thiols bound in the GS-CYN and T(S-CYN)2 adducts 
accounted for 15% (GSH) and 4% (T(SH)2) of reduced thiols present at time point zero. 
Therefore, the binding of CYN to GSH and T(SH)2 could not entirely explain the complete 
depletion of the intracellular thiol pool, and it seemed appropriate to determine a putative 
interaction of CYN with enzymes involved in the formation and regeneration of T(SH)2. For 
this reason, the effect of CYN on ODC, TryS, and TR was studied. 
In T. b. rhodesiense cells treated for 20 min with 50 µM CYN the intracellular 
concentration of ornithine had increased twelve-fold from 4 ± 1 μM to 50 ± 21 μM. DFMO 
treated cells showed concentrations of 48 ± 13 μM after 20 min. It can thus be concluded that 
CYN was a similar strong ODC inhibitor than the positive control DFMO, which is used as a 
drug to treat late stage T. b. gambiense HAT [5]. 
In the case of TryS, 200 µM CYN was added to a standard assay and there was no 
significant inhibition of the enzymes activities (data not shown). To study whether irreversible 
binding occurred, TryS and TR were pre-incubated with CYN for up to 240 min, and the 
remaining activity was measured in the standard assay (Fig. 5). After 240 min of 
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preincubation the activity of TryS was decreased by 51% (Fig. 5A). Also in the case of TR, 
incubation with 100 and 200 µM CYN did not strongly affect the enzymes activity (Fig. 5B). It 
was thus demonstrated, that CYN only weakly inactivates TryS and TR at very high 
concentrations. It is therefore unlikely that TryS or TR are main molecular targets for CYN. 
The TryS assay was done without DDT to rule out the influence of a Michael adduction of 
CYN to DDT occurring (Fig. 5A). 
In summary, it was shown that 50 µM CYN completely depletes intracellular GSH and 
T(SH)2 pools in T. brucei STIB900, via covalent binding of CYN to free sulfhydryl groups of 
GSH and T(SH)2 via a Michael addition, and by inhibition of ODC. These effects combined 
sufficiently explain the potent antitrypanosomal effects of CYN (Fig. 6). 
Discussion  
It is shown, that CYN binds to GSH and T(SH)2 in intact T. b. rhodesiense. The notion 
that STLs reactive enone groups might act as Michael acceptors for sulfhydryl groups in 
biomolecules, has been described before. Kupchan and co-workers in 1970 [11] showed that 
elephantopin, eupatundin, and vernolepin bind covalently via a Michael addition of the α-
methylene-γ-lactone group to the sulfhydryl group of L-cysteine. With an excess of L-
cysteine, elephantopin formed a bisadduct with two L-cysteines through a second addition to 
the other reactive enone moiety. The elephantopin-cysteine adducts were isolated and 
structurally elucidated with 1H-NMR. Schmidt et al. showed that the antitrypanosomal STL 
helenalin [22] formed 2-monoadducts and 2,13-bisadducts with both GSH and cysteine in a 
cell free assay [23]. These adducts too were isolated and structurally elucidated by 1H-NMR. 
Fairlamb et al. [24] showed that melarsoprol, an organo-arsenic drug used to treat 2nd stage 
T. b. rhodesiense HAT, can form a melarsenoxide-trypanothione-complex in vitro, which 
might represent the mode of action of melarsoprol. 
The experimental data proves for the first time that the formation of STL-thiol adducts 
indeed takes place in intact cells, and thus could explain the in vitro activity observed for 
many STLs [7], and the in vivo effects of CYN [6]. All extraction parameters were carefully 
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monitored to ensure adducts were generated in the cells and not extraction artefacts. The 
formation of adducts and depletion of thiols were monitored in a time-dependent manner. 
The uptake of CYN into the cells was efficient, as after 5 min of exposure to 50 µM CYN the 
extracellular CYN concentration was 35 µM, and the total intracellular CYN amounted to 214 
µM (as free CYN, GS-CYN, and T(S-CYN)2).  
Established quantitative HPLC methods for studying cellular GSH and T(SH)2 use 
fluorescent dyes such as monobromobimane or Ellman's reagent for thiol derivatization and 
fluorescence detection [25,26]. In the methodology presented, the complex extraction and 
derivatization steps [24,27] are replaced by a simple two-step extraction with water, and 
subsequent direct analysis by UPLC-MS/MS [28]. The advantages of analyzing T(SH)2 and 
GSH with UHPLC-MS/MS compared to HPLC methods using derivatization, lie in the direct 
detection of thiols/ and thiol adducts with far superior sensitivity in the ppb range. The 
applicability of these extraction and quantification protocols is not limited to trypanosomes, 
but could be applied for studying biological thiols and thiol derivatives in other cellular 
systems. 
In summary, it was shown that the uptake of CYN leads to a rapid and complete 
depletion of GSH and T(SH)2, due to the formation of CYN-thiol adducts and the inhibition of 
ODC. This results in irreversible phenotypic changes of the trypanosomes to a stumpy-like 
form in cell deterioration, and death. Exemplified by CYN this study proves the longstanding 
theory that STLs effect intracellular thiol levels in general and T(SH)2 in particular. 
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Legends for figures 
Fig.1. Structures of the sesquiterpene lactone cynaropicrin (CYN), the parasite main low 
molecular mass thiols glutathione (GSH) and trypanothione (T(SH)2) and the internal 
standards forskolin and EAG. 
 
 
 
Fig.2. 1H NMR spectrum of T(S-CYN)2 bisadduct. 
The 1H NMR spectra of the T(S-CYN)2 bisadduct, T(SH)2 and CYN recorded in 70% H2O and 
30% DMSO-d6. The exocyclic proton signals at position 13 (red color) and position 3’ (blue 
color) of CYN are absent from the adduct. The structural formula represents one of two 
possible isomers. 
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Fig.3. 1H NMR spectrum of GS-CYN monoadduct. 
The 1H NMR spectra of the GS-CYN adduct and CYN measured in 70% H2O and 30% 
DMSO-d6. The exocyclic methylene signals at position 13 of CYN do not appear in the 
adduct. This correlates to a GS-CYN monoadduct, where the GSH is bound to the methylene 
moiety of the lactone.  
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Fig. 4. Quantification of GSH, T(SH)2, and the respective GS-CYN, and T(S-CYN)2. 
Intracellular concentrations were determined for thiol peptides GSH and T(SH)2, CYN-thiol 
adducts, and the extracellular concentration of CYN after exposure to 50 μM CYN for 0, 5, 
10, 20, 30, and 40 min. Quantification was done with at least three independent experiments. 
The phenotypes of the trypanosomes were evaluated at each time point by Giemsa staining 
and light microscopy. Phenotype abbreviations: sl: slender; im: intermediate; s: stumpy-like.  
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Fig. 5. Time dependent inactivation of TcTR and TbTrys by CYN.  
A) TbTryS was pre-incubated with 200 μM CYN and the remaining activity was measured 
after different time points B) TR was pre-incubated with 100 µM or 200 µM CYN in the 
presence of NADPH. Control minutes contained TR and NADPH or TR and CYN, 
respectively.  
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Fig. 6. Overview of potential targets for CYN in the thiol redox metabolism of African 
trypanosomes.  
The Figure presents the biosynthesis of GSH and T(SH)2 in African trypanosomes, and 
shows the direct effects of CYN in different steps of thiol redox metabolism. T(SH)2 is 
synthesized by trypanothione synthetase (TryS) from two molecules of GSH that are linked 
by a spermidine bridge. The spermidine is delivered by spermidine synthase (SpS) from 
putrescine, which in turn is derived from ornithine by ODC. T(SH)2 is maintained in its 
reduced state by trypanothione reductase (TR). Glu: glutamate; Cys: cysteine; GSH1: γ- 
glutamylcysteine synthetase 1; GSH2: γ- glutamylcysteine synthetase 2; GSH: glutathione; 
CYN: cynaropicrin; ODC: ornithine decarboxylase: SpS: spermidine synthase; dSAM: S-
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adenosyl-L-methionine; Sp: spermidine; TryS: trypanothione synthetase; T(SH)2: reduced 
disulfide trypanothione; TR: trypanothione reductase; TS2: disulfide trypanothione. 
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Table 1 
Summary of MS/MS parameters. 
Compound MRM transitions tRa (min) CV (V) CE (eV) LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
CYN 346.7 > 227.02 3.0 32 12 10 156.25 
GSH 308.0 > 179.12 1.0 38 10 10 62.5 
T(SH)2 362.3 > 233.40 2.1 20 20 25 156.25 
T(S-CYN)2-bisadduct 535.3 > 471.39 2.1 39 12 25 93.75 
GS-CYN-monoadduct 654.3 > 524.93 2.4 37 10 50 78.125 
Forskolin 411.0 > 375.20 3.8 20 8 n.d.b n.d.b 
EAG 276.1 > 147.00 0.8 38 10 n.d.b n.d.b 
Ornithine 133.1 > 115.9 1.9 68 9 0.5 7.82 
 
a tR = retention time 
b n.d. = not determined 
c LOD = Limit Of Detection (signal to noise ≥ 3) 
d LLOQ = Lower Limit Of Quantification 
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CHAPTER 6 
General discussion and outlook 
 
6.1. General discussion 
 The typical first step in the process of discovering active compounds against tropical 
diseases has been HTS campaigns of large libraries. Our lead discovery focus relies on 
identifying compounds from natural sources, which are unique regarding their chemical 
diversity, because they have been created by evolution to interact with biological targets. 
Therefore, NPs may show advantages in drug discovery over synthetic compounds. Over the 
last seven years our group collected and tested 724 plants from two out of six floristic realms 
(holarctic and palaeotropical). Additionally, we established a focused library with 64 fungi, 
which were collected in Austria. Fungi remain a relatively poorly studied source of NPs in 
modern drug discovery, especially in antiprotozoal drug discovery despite their species 
richness. With up to 5 million species [1,2] fungi outnumber higher plants by at least 16:1. 
The plants and fungi were extracted resulting in 2151 extracts, which were tested against 
living T. b. rhodesiense, P. falciparum, L. donovani, and T. cruzi [3-6].  
 Among these extracts were 177 produced from traditional used antimalarial Iranian 
plants and from plants, which were reported in European Rennaisance herbal books as 
antimalarial remedies [4,7,8-15]. This leads to the question if extracts from traditionally used 
plants show higher “hit rates” than randomly selected plants. Gyllenhall by himself exactly 
asked this question and showed by analyzing screening results from ethno-medical used 
plants versus randomly selected ones, that traditionally used plants indeed had higher “hit 
rates” and that may thus be better sources for finding active compounds [16]. In our 
antiplasmodial drug discovery screening we observed the same results: When the number of 
hits (defined as more than 50% inhibition at 4.8 μg/mL) from extracts from traditionally used 
antimalarial remedies were compared to those from randomly selected plants we observed a 
five times higher “hit rate” for the ethno-medically used ones (19.7%) over the randomly 
selected ones (4.5%). In our case the plants were documented as antimalarial remedies in 
eight original herbals from 16th and 17th century herbals (Bock, Fuchs, Matthiolus, Lonicerus, 
Brunfels, Zwinger, Tabernaemontanus) from the European Renaissance epoch [7] and as 
Iranian traditional used remedies reported in the books of Biruni, Hooper, Field, Razi, Zargar 
[17-20]. The written documented uses, makes our selection transparent in comparison to 
plants used in purely oral traditions. 
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 In our screening campaign against antiparasitic parasites 2.7% of the plant extracts 
showed activity of more than 50% at 0.81 μg/mL. Those hits were studied using our HPLC-
based activity profiling leading to 110 isolated compounds of which 13 inhibited T. b. 
rhodesiense and 3 inhibited P. falciparum below 0.5 μM. Among those active antiprotozoal 
agents 2 showed poor selectivity with IC50 below 0.5 μM against rat myoblast cells (Figure 6).  
 DNDi, a not for profit research and collaboration body, dedicated to providing novel 
drugs for neglected diseases, recently reported the results from an HTS campaign that used 
the same parasite strains and bioassays to identify new drug candidates against human 
African trypanosomiasis. It was shown that from the tested 87’296 small molecules none had 
an activity below 0.5 μM and that only three of the tested compounds showed 
antitrypanosomal activity between 0.6 and 0.9 μM [21]. This clearly indicates that our 
antiprotozoal drug discovery approach using the diversity of NPs and also the ethno-medical 
selection of plants may deliver more actives than the research of well-connected and 
financial more blessed organizations like DNDi and their partners. 
 The results of this thesis has shown STLs to be among the most promising classes of 
compounds against T. b. rhodesiense as they provide more than the half of the active NPs 
reported here. This is in accordance with other authorities like Schmidt who recently reported 
883 plant derived compounds showing antiprotozoal effects in vitro of which 87 were STLs 
[22,23]. Many in vitro bioactivities in STLs have been described, but CYN reported here, was 
the first plant NP with in vivo activity against T. b. rhodesiense. However, CYN was not able 
to cure T. b. rhodesiense infected mice, but merely reduced the parasitemia. In cooperation 
with Prof. Usuki’s group from Sophia University in Tokyo we successfully synthesized semi-
synthetic derivatives of CYN to gain a better understanding of the structural features, which 
contribute to antitrypanosomal activity. The results of the STL SAR-study demonstrated that 
antitrypanosomal and cytotoxic effect depended on bifunctional α,β-unsaturated exocyclic 
methylene groups such as those found in CYN and in the most active compounds tested in 
this study [24]. These findings were in agreement with Schmidt’s QSAR study of 40 STLs 
against protozoal parasites [25].  
 Many bioactivities of STLs have been attributed to a nucleophilic Michael addition of 
the α-methylene-γ-lactone motif to biological thiols [26]. Kupchan and co-workers in 1970 
[27] showed that elephantopin, eupatundin, and vernolepin bind covalently via a Michael 
addition of the α-methylene-γ-lactone group to the sulfhydryl group of L-cysteine. With an 
excess of L-cysteine, elephantopin formed a bisadduct with two L-cysteines through a 
second addition to the other reactive enone moiety. Schmidt et al. showed that the 
antitrypanosomal pseudoguajanolide STL helenalin formed 2-monoadducts and 2,13-
bisadducts with both GSH and cysteine in a cell free assay [28]. The experimental data in my 
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fifth publication proves for the first time that the formation of STL-thiol adducts indeed takes 
place in intact cells and thus could explain the in vitro activity observed for many STLs and 
the in vivo effects of CYN [11,29]. For this study I established a quantitative UHPLC-based 
MS/MS method, which has the advantage compared to known thiol analysis with HPLC 
methods using derivatization and fluorescent detection [30] that free thiols and thiol adducts 
can be directly detected in a far superior sensitivity. The reported complex extraction model 
and derivatization steps were replaced by a simple two-step protocol with water in 96-well 
format, which allowed directly and rapid analysis of the samples. This method therefore 
represents a significant improvement over existing assays. Their applicability is not limited to 
trypanosomes, but could be applied for studying biological thiols and thiol derivatives in other 
cellular systems. 
 All of the current used drugs against HAT stage 1 and 2 except for DFMO, which 
inhibits ODC, elicit their antitrypanosomal effects by yet unknown or else non specific modes 
of actions: Alsford reported that lysosomal functions is a central role in suramins mode of 
action and combination studies with DFMO resulted in linkage to spermidine synthesis. 
Fairlamb discussed suramin’s trypanocidal effects as well and concluded that interference 
with two key enzymes involved in glycolysis play an important role. Pentamidine’s mode of 
trypanocidal action may collapse the mitochondrial membrane potential, because of its 
millimolar accumulation in the mitochondrion. Melarsoprol, the only available drug for second 
stage T. b. rhodesiense HAT, forms a stable complex with T(SH)2, but whether it is a part of 
the mode of action or metabolism, which might be responsible for its toxicity, remains unclear 
This summary of proposed mode of action of the current available drugs against HAT shows 
that still only DFMO behavior in the trypanosomes is completely known [31]. Therefore, the 
studies on CYN’s mode of action reported here are valuable and unique.  
 CYN’s failure to cure T. b. rhodesiense infected mice led us to try to improve its PK 
profile by masking the α,β-unsaturated exocyclic double bond at the lactone ring. The rational 
for this being that masking of the reactive α,β-unsaturated enone group in the lactone ring 
with an amine would create a prodrug with improved PKs, increased aqueous solubility, and 
reduced unspecific binding to biological thiols via Michael-addition of the α-methylene-γ-
lactone. Through subsequent bioactivation (likely in the liver) the prodrug would be converted 
back to CYN and would display its biological activity on the target. This approach had been 
previously successfully applied to several STLs with anticancer activity like helenalin, 
costunolide, and parthenolide [32]. Sadly though, the lead optimization to improve CYN’s 
bioavailability did not reward any better antitrypanosomal in vivo efficacy after oral 
application. Further PK studies to determine the prodrugs half-life time and plasma 
concentration would be desirable. Another issue, which needs further investigation, is the 
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protein-binding by STL in blood via nucleophilic Michael-addition. In general, 
antitrypanosomal in vivo studies with other orally applied STL amino derivatives are needed 
to demonstrate if the use of amino STLs as prodrugs is a reasonable approach to improving 
STLs suitability as antitrypanosomal drugs.  
 
6.2. Outlook 
The five publications in my PhD thesis covers the early phases of drug discovery for tropical 
diseases using plants and fungi as potential source (Figure 6): The first and the second 
publication describes two antiprotozoal HTS campaigns to find potential active extracts 
(Figure 6; step 1 [4,5]). Our classical HPLC-based activity profiling approach to identify the 
active ingredient in the extract (Figure 6, step 2 [33]) led to the discovery of CYN, the first 
NP, which showed in vivo activity in the acute sleeping sickness mouse model (Figure 6; 
step 3 and 4 [11]). The SAR-study of STLs, reported in the fourth publication [24], 
demonstrated that STLs antitrypanosomal in vitro activity is related to their α,β-unsaturated 
exocyclic doublebond at the lactone and a second active enone moiety such as those found 
in CYN. Those chemical groups function as Michael acceptors and leading to thiol-adducts in 
the trypanosomes, thus entered an apoptotic stage and died (Figure 6, step 5 [29]). This 
mode of action may present a drug discovery model in general and an antitrypanosomal lead 
discovery approach in particular. 
Nevertheless, CYN was not able to cure T. b. rhodesiense infected mice and our attempt to 
increase its PK properties by masking its α,β-unsaturated exocyclic doublebond at the 
lactone did not enhance its efficacy in mice [24]. My personal opinion is that CYN will be 
degratuated fast through the first liver passage by phase I epoxidation at the double bonds, 
which would lead to toxic epoxides, which then may be metabolized by hydrolases to 
secondary alcohol groups or more likely by glutathion-s-transferase to glutathione-
derivatives. Based on the second proposed metabolic path CYNs in vivo toxicity can be 
explained. Then, once the GSH pool is depleted and it therefore can no longer function as 
protector, the epoxides action will be toxic. These phase I reactions followed by phase II 
metabolism steps, which is mostly O-glucuronidation, may lead to the STLs early 
degradation in the first liver passage that might explained why the animals were not cured 
with CYN. The proposed hypothecally metabolism of CYN is described in Figure 7.  
Further PK studies and metabolism CYP450 tests are needed to study CYNs bioavailability 
and to demonstrate if the use of amino STLs as prodrugs and STLs in general are 
reasonable antitrypanosomal clinical drug candidates (Figure 6; step 6).  
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Figure 7. Proposed hypothecally metabolism and excretion pathways of cynaropicrin. GST; glutathione-S-transferase; UGT; UDP-glucuronosyl transferase
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“ Wer wirklich Chemotherapie treiben will, der wird sich ohne weiteres klar zu machen haben, 
dass die Auffindung irgend einer Substanz, die gegen gewisse Infektionen eine Wirkung 
ausübt, immer Sache des Zufalls sein wird; er wird auch sicher nicht erwarten, dass ihm 
gleich auf ersten Anhieb eine optimale Substanz zufliegen wird, sondern er wird vielmehr 
zufrieden sein, wenn er überhaupt Stoffe von einer deutlichen, wenn auch beschränkten 
Wirkungskraft findet.“ 
Paul Ehrlich 1907 
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